BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
Number Citing Articles
1 Giallongo S, Lo Re O, Vinciguerra M. Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers. Cancers (Basel) 2019;11:E676. [PMID: 31096699 DOI: 10.3390/cancers11050676] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Santana-Salgado I, Bautista-Santos A, Moreno-Alcántar R. Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals. Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(22)00025-1. [PMID: 35523684 DOI: 10.1016/j.rgmxen.2021.09.005] [Reference Citation Analysis]
4 Gottlieb A, Best J, Canbay A. Implications of Immunotherapy in Hepatobiliary Tumors. Visc Med 2019;35:18-26. [PMID: 31312646 DOI: 10.1159/000496755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Personeni N, Rimassa L. Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. Lancet Oncol 2021;22:896-8. [PMID: 34051881 DOI: 10.1016/S1470-2045(21)00258-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhou C, Peng Y, Zhou K, Zhang L, Zhang X, Yu L, Hu J, Chen F, Qiu S, Zhou J, Fan J, Ren Z, Wang Z. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:19-28. [PMID: 30881962 DOI: 10.21037/hbsn.2018.11.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Lee CM, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int 2021;15:676-84. [PMID: 33956288 DOI: 10.1007/s12072-021-10190-x] [Reference Citation Analysis]
8 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer 2022. [PMID: 35798825 DOI: 10.1038/s41416-022-01851-1] [Reference Citation Analysis]
10 Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2021:S1590-8658(21)00766-0. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 2021;21:182. [PMID: 33879085 DOI: 10.1186/s12876-021-01765-x] [Reference Citation Analysis]
13 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]
14 Woolen SA, Singal AG, Davenport MS, Troost JP, Khalatbari S, Mittal S, Siddiqui S, Fobar A, Morris J, Odewole M, Tapper EB, Pillai A, Parikh ND. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00202-0. [PMID: 33618022 DOI: 10.1016/j.cgh.2021.02.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
15 Chapiro J, Duncan JS. From Code to Bedside: Introducing Predictive Intelligence to Interventional Oncology. Radiol Artif Intell 2019;1:e190139. [PMID: 32076661 DOI: 10.1148/ryai.2019190139] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. World J Gastrointest Surg 2022; 14(6): 567-579 [DOI: 10.4240/wjgs.v14.i6.567] [Reference Citation Analysis]
17 Macmillan MT, Lim SH, Ireland HM. Diaphragmatic hernia: a rare complication of hepatic ablation. Scott Med J 2020;65:103-6. [PMID: 32677501 DOI: 10.1177/0036933020941498] [Reference Citation Analysis]
18 Zhao S, Zhang X, Wang M, Tan K, Dou W, Fan Q, Li H, Du X, Liu L. Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Ann Transl Med 2020;8:586. [PMID: 32566613 DOI: 10.21037/atm.2020.02.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Yan L, Chen L, Qian K, Kan X, Zhang H, Liang B, Zheng C. Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study. Cancer Manag Res 2021;13:3901-12. [PMID: 34012296 DOI: 10.2147/CMAR.S309310] [Reference Citation Analysis]
20 Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32239989 DOI: 10.1200/EDBK_280625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Costa APDM, da Silva MACN, Castro RS, Sampaio ALDO, Alencar Júnior AM, da Silva MC, Ferreira ADSP. PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil. Viruses 2022;14:732. [DOI: 10.3390/v14040732] [Reference Citation Analysis]
22 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
23 Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. Oncologist 2020;25:e1274-9. [PMID: 31645371 DOI: 10.1634/theoncologist.2019-0718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Yamamichi J, Kawaguchi Y, Otsuka T, Nakashita S, Mizobe H, Eguchi Y, Kimura S. Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans. JGH Open 2020;4:145-52. [PMID: 32280757 DOI: 10.1002/jgh3.12230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
27 Bazzani V, Barchiesi A, Radecka D, Pravisani R, Guadagno A, Di Loreto C, Baccarani U, Vascotto C. Mitochondrial apurinic/apyrimidinic endonuclease 1 enhances mtDNA repair contributing to cell proliferation and mitochondrial integrity in early stages of hepatocellular carcinoma. BMC Cancer 2020;20:969. [PMID: 33028238 DOI: 10.1186/s12885-020-07258-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Franses JW, Bhan I, Zhu AX. PLSec: A novel, liquid biomarker for HCC risk. Med 2021;2:788-90. [DOI: 10.1016/j.medj.2021.06.004] [Reference Citation Analysis]
29 Kudo M. Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma. Liver Cancer 2019;8:73-7. [PMID: 31019898 DOI: 10.1159/000497460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 Giovannini C, Fornari F, Piscaglia F, Gramantieri L. Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells 2021;10:521. [PMID: 33804511 DOI: 10.3390/cells10030521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xie LT, Gu JH, Chai WL, Chen RD, Zhao QY, Kong DX, Jiang TA. Pre-operative Detection of Liver Fibrosis in Hepatocellular Carcinoma Patients Using 2D Shear Wave Elastography: Where to Measure? Ultrasound Med Biol 2020;46:1412-23. [PMID: 32217029 DOI: 10.1016/j.ultrasmedbio.2020.02.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chai B, Wang W, Wang F, Zhou G, Zheng C. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. Int J Hyperthermia 2021;38:1685-94. [PMID: 34843653 DOI: 10.1080/02656736.2021.1970825] [Reference Citation Analysis]
34 Ruzzenente A, Bagante F, Ratti F, Alaimo L, Marques HP, Silva S, Soubrane O, Endo I, Sahara K, Beal EW, Lam V, Poultsides GA, Makris EA, Popescu I, Alexandrescu S, Martel G, Workneh A, Hugh TJ, Guglielmi A, Aldrighetti L, Pawlik TM. Minimally Invasive Versus Open Liver Resection for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension: Results of an International Multi-institutional Analysis. Ann Surg Oncol 2020;27:3360-71. [PMID: 32274662 DOI: 10.1245/s10434-020-08444-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
35 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
37 Zhao Y, Haroun RR, Sahu S, Schernthaner RE, Smolka S, Lin MD, Hong KK, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers (Basel) 2022;14:3615. [PMID: 35892874 DOI: 10.3390/cancers14153615] [Reference Citation Analysis]
38 Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Reference Citation Analysis]
39 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Reference Citation Analysis]
40 Kim DW, Kim SY, Kang HJ, Kang JH, Lee SS, Shim JH, Choi SH, Shin YM, Byun JH. Diagnostic performance of ultrasonography-guided core-needle biopsy according to MRI LI-RADS diagnostic categories. Ultrasonography 2021;40:387-97. [PMID: 33472289 DOI: 10.14366/usg.20110] [Reference Citation Analysis]
41 Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18:603-10. [PMID: 31067134 DOI: 10.1080/14740338.2019.1617272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
43 Ning G, Li Y, Chen W, Tang W, Shou D, Luo Q, Chen H, Zhou Y. Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients. J Oncol 2021;2021:9949492. [PMID: 34335764 DOI: 10.1155/2021/9949492] [Reference Citation Analysis]
44 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
45 Cheng N, Lou B, Wang H. An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing. Nano Res . [DOI: 10.1007/s12274-022-4114-z] [Reference Citation Analysis]
46 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
47 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Spiegelberg J, Iken T, Diener MK, Fichtner-Feigl S. Robotic-Assisted Surgery for Primary Hepatobiliary Tumors-Possibilities and Limitations. Cancers (Basel) 2022;14:265. [PMID: 35053429 DOI: 10.3390/cancers14020265] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
51 Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 2020;40:2008-20. [PMID: 32279446 DOI: 10.1111/liv.14462] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
52 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
53 Kono Y, Sirlin CB, Fetzer DT, Kim TK, Rodgers SK, Piscaglia F, Lyshchik A, Dietrich CF, Wilson SR. Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology 2020;295:245-7. [DOI: 10.1148/radiol.2020192557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6-11. [PMID: 34537584 DOI: 10.1016/j.coph.2021.08.014] [Reference Citation Analysis]
55 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
56 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
57 Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31991869 DOI: 10.3390/cancers12020293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
58 Chen X, Li M, Guo R, Liu W, Li J, Zong X, Chen Q, Wang J. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2022;47:2057-70. [PMID: 35312822 DOI: 10.1007/s00261-022-03484-7] [Reference Citation Analysis]
59 Feng H, Yang C, Xu F, Zhao Y, Jin T, Wei Z, Wang D, Dai C. Therapeutic efficacy of microwave coagulation versus liver resection for hepatocellular carcinoma within the Milan criteria: A propensity score matching analysis. Eur J Surg Oncol 2021:S0748-7983(21)00725-3. [PMID: 34509336 DOI: 10.1016/j.ejso.2021.08.035] [Reference Citation Analysis]
60 Longerich T, Schirmacher P. Emerging Role of the Pathologist in Precision Medicine for HCC. Dig Dis Sci 2019;64:928-33. [PMID: 30815826 DOI: 10.1007/s10620-019-05548-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Magistri P, Catellani B, Frassoni S, Guidetti C, Olivieri T, Assirati G, Caporali C, Pecchi A, Serra V, Ballarin R, Guerrini GP, Bagnardi V, Di Sandro S, Di Benedetto F. Robotic Liver Resection Versus Percutaneous Ablation for Early HCC: Short- and Long-Term Results. Cancers (Basel) 2020;12:E3578. [PMID: 33266096 DOI: 10.3390/cancers12123578] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Remington TL, Osman M, Simmonds K, Charlton C, Doucette K. Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B. CanLivJ 2020;3:263-75. [DOI: 10.3138/canlivj.2019-0024] [Reference Citation Analysis]
63 Sun B, Zhang W, Chen L, Sun T, Ren Y, Zhu L, Qian K, Zheng C. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus. Abdom Radiol (NY) 2022;47:858-68. [PMID: 34820688 DOI: 10.1007/s00261-021-03349-5] [Reference Citation Analysis]
64 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
65 Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology 2020;72:2197-205. [PMID: 32602980 DOI: 10.1002/hep.31440] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
66 Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 2021;17:209-15. [PMID: 32757461 DOI: 10.1111/ajco.13361] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Reference Citation Analysis]
68 Yakkala C, Chiang CL, Kandalaft L, Denys A, Duran R. Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. Front Immunol 2019;10:2283. [PMID: 31608067 DOI: 10.3389/fimmu.2019.02283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
69 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D; Cochrane Hepato-Biliary Group. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013362] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Zhang D, Wei Q, Wu GG, Zhang XY, Lu WW, Lv WZ, Liao JT, Cui XW, Ni XJ, Dietrich CF. Preoperative Prediction of Microvascular Invasion in Patients With Hepatocellular Carcinoma Based on Radiomics Nomogram Using Contrast-Enhanced Ultrasound. Front Oncol 2021;11:709339. [PMID: 34557410 DOI: 10.3389/fonc.2021.709339] [Reference Citation Analysis]
71 Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One 2020;15:e0230005. [PMID: 32163475 DOI: 10.1371/journal.pone.0230005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
72 Liang TT, Shao Q, Deng ZC, Wang T, Kang QZ. Systemic Expression Analysis Reveals Prognostic Significance of WIPI3 in Hepatocellular Carcinoma. Front Genet 2020;11:847. [PMID: 32973867 DOI: 10.3389/fgene.2020.00847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Starlinger P, Ubl DS, Hackl H, Starlinger J, Nagorney DM, Smoot RL, Habermann EB, Cleary SP. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open 2021;5:zraa043. [PMID: 33609383 DOI: 10.1093/bjsopen/zraa043] [Reference Citation Analysis]
74 Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res 2021;51:1229-41. [PMID: 34591334 DOI: 10.1111/hepr.13718] [Reference Citation Analysis]
75 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Lau WY, Wang SF, Guan Y, Chen XP, Huang ZY. Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. J Hepatocell Carcinoma 2022;9:633-47. [PMID: 35909916 DOI: 10.2147/JHC.S368302] [Reference Citation Analysis]
76 Schoenberg MB, Anger HJW, Bucher JN, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visc Med 2020;36:506-15. [PMID: 33447607 DOI: 10.1159/000506752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Owens AR, McInerney CE, Prise KM, McArt DG, Jurek-Loughrey A. Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (Hepatocellular carcinoma). BMC Bioinformatics 2021;22:563. [PMID: 34819028 DOI: 10.1186/s12859-021-04454-4] [Reference Citation Analysis]
78 Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:517-523. [PMID: 31524775 DOI: 10.1097/MEG.0000000000001528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Sui MH, Wang HG, Chen MY, Wan T, Hu BY, Pan YW, Li H, Cai HY, Cui C, Lu SC. Assessment of the effect of the Aquamantys® system on local recurrence after hepatectomy for hepatocellular carcinoma through propensity score matching. Clin Transl Oncol 2019;21:1634-43. [DOI: 10.1007/s12094-019-02092-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Paisant A, Gillard M, Oberti F, Roux M, Aubé C. Validation of a Diagnostic Algorithm for Hepatocellular Carcinoma at Gadoxetic Acid-enhanced MRI. Radiology 2021;300:184-6. [PMID: 33904774 DOI: 10.1148/radiol.2021204529] [Reference Citation Analysis]
81 Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
82 Darnell A, Belmonte E, Reig M, Brú C. Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma. Radiologia (Engl Ed) 2018;60:424-36. [PMID: 30196841 DOI: 10.1016/j.rx.2018.05.004] [Reference Citation Analysis]
83 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
84 Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J, Todica A, Gildehaus FJ, Kunz WG, Stahl R, Spitzweg C, Ricke J, Kazmierczak PM. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 2019;19:73. [PMID: 31727170 DOI: 10.1186/s40644-019-0263-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
85 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Vernuccio F, Cannella R, Cabibbo G, Greco S, Celsa C, Matteini F, Giuffrida P, Midiri M, Di Marco V, Cammà C, Brancatelli G. Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. Diagnostics 2022;12:1187. [DOI: 10.3390/diagnostics12051187] [Reference Citation Analysis]
87 Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20201928. [PMID: 33835138 DOI: 10.1042/BSR20201928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ju S, Zhou C, Yang C, Wang C, Liu J, Wang Y, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Front Oncol 2022;11:835889. [DOI: 10.3389/fonc.2021.835889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
89 Saud LRC, Chagas AL, Maccali C, Pinto PVA, Horvat N, Alencar RSSM, Tani CM, Abdala E, Carrilho FJ. Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior? Eur J Gastroenterol Hepatol 2021;33:583-8. [PMID: 33560682 DOI: 10.1097/MEG.0000000000002057] [Reference Citation Analysis]
90 Long Y, Zeng Q, He X, Ye H, Su Y, Zheng R, Yu J, Xu E, Li K. One-lung ventilation for percutaneous thermal ablation of liver tumors in the hepatic dome. Int J Hyperthermia 2020;37:49-54. [PMID: 31918592 DOI: 10.1080/02656736.2019.1708483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2020;115:1289-92. [PMID: 32453041 DOI: 10.14309/ajg.0000000000000676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
93 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
94 Bengtsson B, Askling J, Ludvigsson JF, Hagström H. Validity of administrative codes associated with cirrhosis in Sweden. Scandinavian Journal of Gastroenterology 2020;55:1205-10. [DOI: 10.1080/00365521.2020.1820566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
95 Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y, Qiu Y, Zhang Z, Li M, Jiang Y, Zhao J, Du H, Zhang Z, Lu W, Zhang Y. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. Biomed Res Int 2020;2020:4037639. [PMID: 33163533 DOI: 10.1155/2020/4037639] [Reference Citation Analysis]
96 Chinnaratha MA, Campbell K, Mathias R, McCormick RJ, Woodman RJ, Wigg AJ. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. J Gastrointest Cancer 2019;50:888-93. [PMID: 30345486 DOI: 10.1007/s12029-018-0171-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Terzi E, Giamperoli A, Iavarone M, Leoni S, De Bonis L, Granito A, Forgione A, Tovoli F, Piscaglia F. Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers (Basel) 2022;14:336. [PMID: 35053498 DOI: 10.3390/cancers14020336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J; Spanish Society of Liver Transplantation (SETH) Consensus Panel. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021;105:602-7. [PMID: 32345868 DOI: 10.1097/TP.0000000000003281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
100 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
101 El-Derany MO. Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis. Biology (Basel) 2020;9:E75. [PMID: 32283835 DOI: 10.3390/biology9040075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
102 Lee HA, Seo YS, Shin I, Yoon WS, Lee HY, Rim CH. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. International Journal of Surgery 2022;104:106753. [DOI: 10.1016/j.ijsu.2022.106753] [Reference Citation Analysis]
103 Heo S, Kim DW, Choi SH, Kim SW, Jang JK. Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis. Eur Radiol. [DOI: 10.1007/s00330-021-08436-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Ni X, Lin Z, Dai S, Chen H, Chen J, Zheng C, Wu B, Ao J, Shi K, Sun H. Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma. J Cell Biochem 2020;121:3626-41. [PMID: 32065423 DOI: 10.1002/jcb.29656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Raoul JL, Faivre S, Frenel JS, Rimassa L. Medical oncologists must get more involved in systemic treatment. Ann Oncol 2019;30:6-8. [PMID: 32081277 DOI: 10.1093/annonc/mdy471] [Reference Citation Analysis]
106 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
108 Heinrich S, Watzka F, Lang H. Integrative Concepts for Liver Surgery. Visc Med 2020;36:351-8. [PMID: 33178731 DOI: 10.1159/000511043] [Reference Citation Analysis]
109 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
110 Cui H, Rong W, Ma J, Zhu Q, Jiang B, Zhang L, Li C, Zhuo Z, Chen M. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma. Gene 2022;822:146353. [PMID: 35189250 DOI: 10.1016/j.gene.2022.146353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Lee IJ, Lee JH, Lee YB, Kim YJ, Yoon JH, Yin YH, Lee M, Hur S, Kim HC, Jae HJ, Chung JW. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Ther Adv Med Oncol 2019;11:1758835919866072. [PMID: 31447948 DOI: 10.1177/1758835919866072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
112 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
113 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
114 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 62.0] [Reference Citation Analysis]
115 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
116 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2021;28:1464-76. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
117 Kim J, Min JH, Kim SK, Shin SY, Lee MW. Detection of Hepatocellular Carcinoma in Contrast-Enhanced Magnetic Resonance Imaging Using Deep Learning Classifier: A Multi-Center Retrospective Study. Sci Rep 2020;10:9458. [PMID: 32527998 DOI: 10.1038/s41598-020-65875-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
118 Fateen W, Johnson PJ, Wood HM, Zhang H, He S, El-Meteini M, Wyatt JI, Aithal GP, Quirke P. Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA. J Pathol 2021;255:30-40. [PMID: 34028025 DOI: 10.1002/path.5734] [Reference Citation Analysis]
119 Ziol M. [Liver tumor pathology seminar. Case 7]. Ann Pathol 2021;41:449-53. [PMID: 34420807 DOI: 10.1016/j.annpat.2021.02.009] [Reference Citation Analysis]
120 Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, Ganger D, Maddur H, Moore C, Hohlastos E, Katariya N, Caicedo JC, Kalyan A, Lewandowski RJ, Salem R. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72:1151-1158. [PMID: 32145255 DOI: 10.1016/j.jhep.2020.02.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
121 Fan PL, Xia HS, Ding H, Dong Y, Chen LL, Wang WP. Characterization of Early Hepatocellular Carcinoma and High-Grade Dysplastic Nodules on Contrast-Enhanced Ultrasound: Correlation With Histopathologic Findings. J Ultrasound Med 2020;39:1799-808. [PMID: 32378794 DOI: 10.1002/jum.15288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Shin J, Lee S, Yoon JK, Chung YE, Choi J, Park M. LI‐RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. J Magn Reson Imaging 2021;54:518-25. [DOI: 10.1002/jmri.27570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
123 Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clin Imaging 2021;78:194-200. [PMID: 34022765 DOI: 10.1016/j.clinimag.2021.05.007] [Reference Citation Analysis]
124 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
125 Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association Française pour l’Etude du Foie (AFEF). Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45:101590. [PMID: 33780876 DOI: 10.1016/j.clinre.2020.101590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Tsilimigras DI, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. Ann Surg Oncol 2020;27:866-74. [DOI: 10.1245/s10434-019-08025-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
127 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Chen BW, Zhou Y, Wei T, Wen L, Zhang YB, Shen SC, Zhang J, Ma T, Chen W, Ni L, Wang Y, Bai XL, Liang TB. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. J Cell Biochem 2021;122:130-42. [PMID: 32951268 DOI: 10.1002/jcb.29844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
129 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
130 Christou CD, Tsoulfas G. Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities. World J Gastrointest Oncol 2022; 14(4): 765-793 [DOI: 10.4251/wjgo.v14.i4.765] [Reference Citation Analysis]
131 Zhou Q, Zhou Q, Liu Q, He Z, Yan Y, Lin J, Chen Z, He C, Mao K, Wang J, Zhou Z, Xiao Z, Zhang J. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK. Theranostics 2020;10:10345-59. [PMID: 32929353 DOI: 10.7150/thno.42069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
133 Citone M, Fanelli F, Falcone G, Mondaini F, Cozzi D, Miele V. A closer look to the new frontier of artificial intelligence in the percutaneous treatment of primary lesions of the liver. Med Oncol 2020;37:55. [PMID: 32424627 DOI: 10.1007/s12032-020-01380-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
134 Philips CA, Ahamed R, Rajesh S, George T, Mohanan M, Augustine P. Update on diagnosis and management of sepsis in cirrhosis: Current advances. World J Hepatol 2020; 12(8): 451-474 [PMID: 32952873 DOI: 10.4254/wjh.v12.i8.451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
135 Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
136 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Beudeker BJB, Groothuismink ZMA, de Man RA, Witjes CDM, van der Eijk AA, Boonstra A, Sonneveld MJ. Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study. J Viral Hepat 2021;28:205-8. [PMID: 32869922 DOI: 10.1111/jvh.13394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
139 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
140 Yi D, Wen-Ping W, Lee WJ, Meloni MF, Clevert DA, Cristina Chammas M, Tannapfel A, Forgione A, Dietrich CF. Hepatocellular carcinoma in the non-cirrhotic liver. Clin Hemorheol Microcirc 2021. [PMID: 34842182 DOI: 10.3233/CH-211309] [Reference Citation Analysis]
141 Bae JS, Lee DH, Lee SM, Suh KS, Lee KW, Yi NJ, Lee KB, Kim H, Han JK. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35138137 DOI: 10.2214/AJR.21.27186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Liu Y, Ren Y, Ge S, Xiong B, Zhou G, Feng G, Song S, Zheng C. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. Front Oncol 2021;11:662408. [PMID: 34155478 DOI: 10.3389/fonc.2021.662408] [Reference Citation Analysis]
143 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
144 Wu X, Ge L, Shen G, He Y, Xu Z, Li D, Mu C, Zhao L, Zhang W. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022;14:21848-59. [PMID: 35507826 DOI: 10.1021/acsami.2c00211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Li S, Huang J, Yang F, Zeng H, Tong Y, Li K. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2021;11:11078. [PMID: 34040099 DOI: 10.1038/s41598-021-90507-w] [Reference Citation Analysis]
146 Hassouna MM, Naguib M, Radwan EM, Abdel-Samiee M, Estaphan S, Abdelsameea E. DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:3357-63. [PMID: 33247696 DOI: 10.31557/APJCP.2020.21.11.3357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Yeung R, Beaton L, Rackley T, Weber B, Hamm J, Lee R, Camborde M, Pearson M, Duzenli C, Loewen S, Liu M, Ma R, Schellenberg D. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas. Clinical Oncology 2019;31:365-73. [DOI: 10.1016/j.clon.2019.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
148 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Reference Citation Analysis]
149 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Zheng W, Huang H, She D, Xiong M, Chen X, Lin X, Cao D. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY) 2022;47:957-68. [PMID: 34964069 DOI: 10.1007/s00261-021-03380-6] [Reference Citation Analysis]
151 Celsa C, Cabibbo G, Pagano D, di Marco V, Cammà C, Gruttadauria S. Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. J Laparoendosc Adv Surg Tech A 2020;30:1048-53. [PMID: 32668179 DOI: 10.1089/lap.2020.0471] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Wu J, Zhou X, Li P, Lin X, Wang J, Hu Z, Zhang P, Chen D, Cai H, Niessner R, Haisch C, Sun P, Zheng Y, Jiang Z, Zhou H. Ultrasensitive and Simultaneous SERS Detection of Multiplex MicroRNA Using Fractal Gold Nanotags for Early Diagnosis and Prognosis of Hepatocellular Carcinoma. Anal Chem 2021;93:8799-809. [PMID: 34076420 DOI: 10.1021/acs.analchem.1c00478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
153 Zhao Q, Xie L, Chen S, Xu X, Jiang T, Zheng S. Virtual navigation-guided radiofrequency ablation for recurrent hepatocellular carcinoma invisible on ultrasound after hepatic resection. Hepatobiliary & Pancreatic Diseases International 2020;19:532-40. [DOI: 10.1016/j.hbpd.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
155 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
156 Mueller PP, Chen Q, Ayer T, Nemutlu G, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
157 Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533-9. [PMID: 32151618 DOI: 10.1016/j.jhep.2020.02.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
158 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Abdel-Moety A, Baddour N, Salem P, Rady A, El-Shendidi A. ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation. Clin Exp Hepatol 2022;8:49-59. [PMID: 35415261 DOI: 10.5114/ceh.2022.114172] [Reference Citation Analysis]
161 Ballotin VR, Bigarella LG, Soldera J, Soldera J. Deep learning applied to the imaging diagnosis of hepatocellular carcinoma. Artif Intell Gastrointest Endosc 2021; 2(4): 127-135 [DOI: 10.37126/aige.v2.i4.127] [Reference Citation Analysis]
162 Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther 2020;13:10267-73. [PMID: 33116607 DOI: 10.2147/OTT.S261521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Sun Y, Chen ZY, Gan X, Dai H, Cai D, Liu RH, Zhou JM, Zhang HL, Li ZH, Luo QQ, Jiang S, Wang T, Zhang KH. A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma. Scand J Gastroenterol 2022;:1-11. [PMID: 35512233 DOI: 10.1080/00365521.2022.2069476] [Reference Citation Analysis]
164 Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Acta Clin Belg 2022;:1-9. [PMID: 35587164 DOI: 10.1080/17843286.2022.2076791] [Reference Citation Analysis]
165 Verloh N, Jensch I, Lürken L, Haimerl M, Dollinger M, Renner P, Wiggermann P, Werner JM, Zeman F, Stroszczynski C, Beyer LP. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors. Radiol Oncol 2019;53:116-22. [PMID: 30840591 DOI: 10.2478/raon-2019-0011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
166 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
167 Hamada M, Ueshima E, Ishihara T, Koide Y, Okada T, Horinouchi H, Ishida J, Mayahara H, Sasaki K, Gentsu T, Sofue K, Yamaguchi M, Sasaki R, Sugimoto K, Murakami T. The feasibility of transcatheter arterial chemoembolization following radiation therapy for hepatocellular carcinoma. Acta Radiol Open 2021;10:20584601211034965. [PMID: 34394958 DOI: 10.1177/20584601211034965] [Reference Citation Analysis]
168 Lacroix M, Mulé S, Herin E, Pigneur F, Richard P, Zegai B, Baranes L, Djabbari M, Brunetti F, de'Angelis N, Laurent A, Tacher V, Kobeiter H, Luciani A. Virtual unenhanced imaging of the liver derived from 160-mm rapid-switching dual-energy CT (rsDECT): Comparison of the accuracy of attenuation values and solid liver lesion conspicuity with native unenhanced images. Eur J Radiol 2020;133:109387. [PMID: 33166833 DOI: 10.1016/j.ejrad.2020.109387] [Reference Citation Analysis]
169 Watanabe M, Yokomori H, Takahashi Y, Okada T, Shibuya A, Koizumi W. Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. Turk J Gastroenterol 2019;30:541-8. [PMID: 31144660 DOI: 10.5152/tjg.2019.18654] [Reference Citation Analysis]
170 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
171 Bargellini I, Scalise P, Boni G, Traino CA, Bozzi E, Lorenzoni G, Crocetti L, Cioni R. Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score. J Vasc Interv Radiol 2020;31:2028-32. [PMID: 33121865 DOI: 10.1016/j.jvir.2020.06.027] [Reference Citation Analysis]
172 You Y, Long Y, Yan R, Luo L, Zhang M, Li L, Zeng Q, Li K, Zheng R, Xu E. Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study. Front Oncol 2021;11:570312. [PMID: 33732639 DOI: 10.3389/fonc.2021.570312] [Reference Citation Analysis]
173 Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
174 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Alqahtani SA, Colombo M. Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approach. Ann Transl Med 2020;8:1255. [PMID: 33178787 DOI: 10.21037/atm-2020-79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Bae JS, Lee JM, Yoon JH, Jang S, Chung JW, Lee KB, Yi NJ, Lee JH. How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT. Liver Cancer 2020;9:293-307. [PMID: 32647632 DOI: 10.1159/000505191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
177 Pesi B, Bencini L, Moraldi L, Tofani F, Batignani G, Bechi P, Farsi M, Annecchiarico M, Coratti A. Robotic Versus Open Liver Resection in Hepatocarcinoma: Surgical and Oncological Outcomes. Surg Laparosc Endosc Percutan Tech 2021;31:468-74. [PMID: 33480668 DOI: 10.1097/SLE.0000000000000904] [Reference Citation Analysis]
178 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Mocan T, Stiufiuc R, Popa C, Nenu I, Pestean C, Nagy AL, Mocan LP, Leucuta DC, Hajjar NA, Sparchez Z. Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. Sci Rep 2021;11:1316. [PMID: 33446793 DOI: 10.1038/s41598-020-79917-4] [Reference Citation Analysis]
180 Curran C, Stanley AJ, Barclay ST, Priest M, Graham J. The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34689659 DOI: 10.1080/17474124.2021.1997586] [Reference Citation Analysis]
181 Lai Q, Di Martino M, Lucatelli P, Mennini G. Locoregional therapy response in patients with hepatocellular cancer waiting for liver transplantation: Only selection or biological effect? World J Gastroenterol 2018; 24(31): 3469-3471 [PMID: 30131653 DOI: 10.3748/wjg.v24.i31.3469] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
182 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
183 Zhang H, Du X, Dong H, Xu W, Zhou P, Liu S, Qing X, Zhang Y, Yang M, Zhang Y. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol 2022;22:348. [PMID: 35854221 DOI: 10.1186/s12876-022-02424-5] [Reference Citation Analysis]
184 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
185 Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Reference Citation Analysis]
186 Kim SY. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria? Clin Mol Hepatol 2020;26:309-11. [PMID: 32536046 DOI: 10.3350/cmh.2020.0061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
187 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
188 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Reference Citation Analysis]
189 Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2022;47:596-607. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
190 Piñero F, Rubinstein F, Laurent A, Silva M, Cherqui D, Duvoux C. Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation". Ann Surg 2021;274:e832-3. [PMID: 33214429 DOI: 10.1097/SLA.0000000000004511] [Reference Citation Analysis]
191 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Zhou C, Xia Y, Wei Y, Cheng L, Wei J, Guo B, Meng F, Cao S, van Hest JCM, Zhong Z. GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma. Acta Biomater 2020;113:512-21. [PMID: 32562803 DOI: 10.1016/j.actbio.2020.06.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
193 Liu S, Xu Z, Fang Z, Zhang D, Qin Z, Fan L, Duan J, Yin H, Zhang Y, Pang Q, Tan Y. The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma. Int J Gen Med 2021;14:4291-301. [PMID: 34408472 DOI: 10.2147/IJGM.S323293] [Reference Citation Analysis]
194 Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. Int J Mol Sci 2021;22:4173. [PMID: 33920670 DOI: 10.3390/ijms22084173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Bonel-Pérez GC, Pérez-Jiménez A, Gris-Cárdenas I, Parra-Pérez AM, Lupiáñez JA, Reyes-Zurita FJ, Siles E, Csuk R, Peragón J, Rufino-Palomares EE. Antiproliferative and Pro-Apoptotic Effect of Uvaol in Human Hepatocarcinoma HepG2 Cells by Affecting G0/G1 Cell Cycle Arrest, ROS Production and AKT/PI3K Signaling Pathway. Molecules 2020;25:E4254. [PMID: 32947962 DOI: 10.3390/molecules25184254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
197 Yang Q, Wei J, Hao X, Kong D, Yu X, Jiang T, Xi J, Cai W, Luo Y, Jing X, Yang Y, Cheng Z, Wu J, Zhang H, Liao J, Zhou P, Song Y, Zhang Y, Han Z, Cheng W, Tang L, Liu F, Dou J, Zheng R, Yu J, Tian J, Liang P. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: A multicentre study. EBioMedicine. 2020;56:102777. [PMID: 32485640 DOI: 10.1016/j.ebiom.2020.102777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
198 Lv JY, Zhang NN, Du YW, Wu Y, Song TQ, Zhang YM, Qu Y, Liu YX, Gu J, Wang ZY, Qiu YB, Yang B, Tian DZ, Guo QJ, Zhang L, Sun JS, Xie Y, Wang ZL, Sun X, Jiang WT, Lu W. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II. Yonsei Med J 2021;62:29-40. [PMID: 33381932 DOI: 10.3349/ymj.2021.62.1.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 Lee DH, Lee JM, Yu MH, Hur BY, Yi N, Lee K, Suh K, Yoon J, Kim YJ, Lee J, Yu SJ, Han JK. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. Eur Radiol 2019;29:3122-31. [DOI: 10.1007/s00330-018-5941-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
200 Malik J, Klammer M, Rolny V, Chan HLY, Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, Swiatek-de Lange M. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. World J Gastroenterol 2022; 28(29): 3917-3933 [DOI: 10.3748/wjg.v28.i29.3917] [Reference Citation Analysis]
201 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
202 Kawanami GH, Katsuda L, Rocha TB, da Silva Yamashiro F, Pelafsky L, Qi X, Romeiro FG. How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience. Can J Gastroenterol Hepatol 2021;2021:6219896. [PMID: 33614533 DOI: 10.1155/2021/6219896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Xu G, Zhou X, Xing J, Xiao Y, Jin B, Sun L, Yang H, Du S, Xu H, Mao Y. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell Int 2020;20:547. [PMID: 33292241 DOI: 10.1186/s12935-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
204 Cannella R, Cammà C, Matteini F, Celsa C, Giuffrida P, Enea M, Comelli A, Stefano A, Cammà C, Midiri M, Lagalla R, Brancatelli G, Vernuccio F. Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. Diagnostics 2022;12:1308. [DOI: 10.3390/diagnostics12061308] [Reference Citation Analysis]
205 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
206 Norén S, Bengtsson B, Hagström H, Ljunggren G, Wahlin S. Hepatocellular carcinoma in Stockholm, Sweden 2003-2018: a population-based cohort study. Scand J Gastroenterol 2022;:1-9. [PMID: 35605144 DOI: 10.1080/00365521.2022.2062257] [Reference Citation Analysis]
207 Gatti P, Giorgio A, Ciracì E, Roberto I, Anglani A, Sergio S, Rizzello F, Giorgio V, Semeraro S. Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. J Ultrasound 2019;22:363-70. [PMID: 30864004 DOI: 10.1007/s40477-019-00361-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
208 Laroia ST, Yadav K, Kumar S, Rastogi A, Kumar G, Sarin SK. Material decomposition using iodine quantification on spectral CT for characterising nodules in the cirrhotic liver: a retrospective study. Eur Radiol Exp 2021;5:22. [PMID: 34046753 DOI: 10.1186/s41747-021-00220-6] [Reference Citation Analysis]
209 Degasperi E, D'Ambrosio R, Lampertico P. Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma-authors' reply. Aliment Pharmacol Ther 2022;55:124-5. [PMID: 34907557 DOI: 10.1111/apt.16710] [Reference Citation Analysis]
210 Ko SE, Lee MW, Min JH, Ahn SH, Rhim H, Kang TW, Song KD, Kim JM, Choi GS, Cha DI, Lim HK. Laparoscopic radiofrequency ablation of subcapsular hepatocellular carcinomas: risk factors related to a technical failure. Surg Endosc 2021. [PMID: 33523278 DOI: 10.1007/s00464-021-08310-7] [Reference Citation Analysis]
211 Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-24. [PMID: 31182766 DOI: 10.1038/s41416-019-0488-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
212 Gao F, Wei Y, Zhang T, Jiang H, Li Q, Yuan Y, Yao S, Ye Z, Wan S, Wei X, Nie L, Tang H, Song B. New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Front Oncol 2022;12:812832. [PMID: 35356206 DOI: 10.3389/fonc.2022.812832] [Reference Citation Analysis]
213 Takahashi K, Gosho M, Kim J, Shimomura O, Miyazaki Y, Furuya K, Akashi Y, Enomoto T, Hashimoto S, Oda T. Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage. J Am Coll Surg 2022;234:155-65. [PMID: 35213436 DOI: 10.1097/XCS.0000000000000027] [Reference Citation Analysis]
214 Lin K, Huang Q, Wang L, Zeng J, Ding Z, Liu H, Fu J, Guo P, Chen Z, Zeng Y, Zhou W, Liu J. Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol 2021;11:612588. [PMID: 33680963 DOI: 10.3389/fonc.2021.612588] [Reference Citation Analysis]
215 Hernandez-Meza G, Vietti Violi N, Said D, Novogrodsky E, Villavisanis D, Maron SZ, Frere J, Schiano TD, Friedman S, Boffetta P, Branch A, Taouli B. MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdom Radiol (NY) 2021;46:5142-51. [PMID: 34283266 DOI: 10.1007/s00261-021-03212-7] [Reference Citation Analysis]
216 Sparkman J, Hernaez R, El-Serag HB. Traditional Chinese Medicine to the rescue of allopathic medicine in the co-adjuvant treatment of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:97. [PMID: 30603733 DOI: 10.21037/tgh.2018.11.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
217 Li Z, Hu Y, Zeng Q, Wang H, Yan J, Li H, Yu Z. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int 2019;19:211. [PMID: 31413665 DOI: 10.1186/s12935-019-0926-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
218 Roth GS, Hernandez O, Daabek N, Brusset B, Teyssier Y, Ghelfi J, Hilleret MN, Sengel C, Bricault I, Decaens T, Costentin C. Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1634. [PMID: 35406406 DOI: 10.3390/cancers14071634] [Reference Citation Analysis]
219 Marquardt JU, Saborowski A, Czauderna C, Vogel A. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Target Oncol. 2019;14:115-123. [PMID: 30805831 DOI: 10.1007/s11523-019-00624-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
220 Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:149-59. [PMID: 34007796 DOI: 10.14218/JCTH.2020.00125] [Reference Citation Analysis]
221 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
222 Lee S, Kim SS, Roh YH, Choi JY, Park MS, Kim MJ. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Int 2020;40:1488-97. [PMID: 32145134 DOI: 10.1111/liv.14424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
223 Lei GY, Shen L, Junnarkar SP, Huey CT, Low J, Shelat VG. Predictors of 90-Day Mortality following Hepatic Resection for Hepatocellular Carcinoma. Visc Med 2021;37:102-9. [PMID: 33981750 DOI: 10.1159/000510811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
224 Schultheiß M, Bengsch B, Thimme R. [Hepatocellular Carcinoma]. Dtsch Med Wochenschr 2021;146:1411-20. [PMID: 34670284 DOI: 10.1055/a-1226-3047] [Reference Citation Analysis]
225 Zheng H, Liu K, Yang Y, Liu B, Zhao X, Chen Y, Feng Y, Meng M, Tan X, Zhu Q. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score–matched study. Eur Radiol. [DOI: 10.1007/s00330-022-08537-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Feng ZH, Wang MD, Chen Z, Sun LY, Xu X, Kong QY, Chen ZX, Zeng YY, Liang YJ, Chen ZY, Wang H, Zhou YH, Chen TH, Yao LQ, Li C, Pawlik TM, Lau WY, Shen F, Yang T. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study. Surgery 2022:S0039-6060(22)00408-1. [PMID: 35868902 DOI: 10.1016/j.surg.2022.05.023] [Reference Citation Analysis]
227 Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:935-944.e3. [PMID: 31419571 DOI: 10.1016/j.cgh.2019.08.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 18.7] [Reference Citation Analysis]
228 Li L, Zheng W, Wang J, Han J, Guo Z, Hu Y, Li X, Zhou J. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection. AJR Am J Roentgenol 2022. [PMID: 35441534 DOI: 10.2214/AJR.22.27521] [Reference Citation Analysis]
229 Hubner RA, Reeves HL, Edeline J. Combined hepatocellular-cholangiocarcinoma - More questions than answers. Liver Int 2021;41:1186-8. [PMID: 34002474 DOI: 10.1111/liv.14894] [Reference Citation Analysis]
230 Skef W, Agarwal M, Mikolajczyk AE. Position 1: Transarterial Chemoembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocelluar Carcinoma. Clinical Liver Disease 2020;15:71-3. [DOI: 10.1002/cld.909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Martelletti C, Armandi A, Caviglia GP, Saracco GM, Pellicano R. Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterol (Torino) 2021;67:196-208. [PMID: 32677420 DOI: 10.23736/S2724-5985.20.02747-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Zanus G, Tagliente G, Rossi S, Bonis A, Zambon M, Scopelliti M, Brizzolari M, Grossi U, Romano M, Finotti M. Pulsed Microwave Liver Ablation: An Additional Tool to Treat Hepatocellular Carcinoma. Cancers (Basel) 2022;14:748. [PMID: 35159014 DOI: 10.3390/cancers14030748] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Reference Citation Analysis]
234 Casellas-Robert M, Lim C, Lopez-Ben S, Lladó L, Salloum C, Codina-Font J, Comas-Cufí M, Ramos E, Figueras J, Azoulay D. Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. World J Surg 2020;44:3915-22. [PMID: 32661688 DOI: 10.1007/s00268-020-05687-9] [Reference Citation Analysis]
235 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11(1): 50-64 [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
236 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
237 Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
238 Hou Z, Zhu K, Yang X, Chen P, Zhang W, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. Ann Transl Med 2020;8:1047. [PMID: 33145266 DOI: 10.21037/atm-20-2990] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
239 Bruix J, Ayuso C. Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty. Gastroenterology 2019;156:860-2. [PMID: 30776351 DOI: 10.1053/j.gastro.2019.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
240 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
241 Leuchte K, Staib E, Thelen M, Gödel P, Lechner A, Zentis P, Garcia-Marquez M, Waldschmidt D, Datta RR, Wahba R, Wybranski C, Zander T, Quaas A, Drebber U, Stippel DL, Bruns C, von Bergwelt-Baildon M, Wennhold K, Schlößer HA. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:893-907. [PMID: 33006650 DOI: 10.1007/s00262-020-02734-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
242 Famularo S, Di Sandro S, Giani A, Bernasconi DP, Lauterio A, Ciulli C, Rampoldi AG, Corso R, De Carlis R, Romano F, Braga M, Gianotti L, De Carlis L. Treatment of hepatocellular carcinoma beyond the Milan criteria. A weighted comparative study of surgical resection versus chemoembolization. HPB (Oxford) 2020;22:1349-58. [PMID: 31932243 DOI: 10.1016/j.hpb.2019.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies. Acta Oncol 2020;59:888-94. [PMID: 32216593 DOI: 10.1080/0284186X.2020.1741679] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
244 Manning C, Alam SM. Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma". J Hepatol 2020;73:1269-70. [PMID: 32807575 DOI: 10.1016/j.jhep.2020.06.009] [Reference Citation Analysis]
245 Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, Hubner RA. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol 2021;47:401-8. [PMID: 32958370 DOI: 10.1016/j.ejso.2020.08.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
246 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-34. [PMID: 34012661 DOI: 10.21037/jgo-20-332] [Reference Citation Analysis]
247 Nie G, Peng D, Li B, Lu J, Xiong X. Diagnostic Accuracy of Circular RNAs in Different Types of Samples for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:794105. [PMID: 34992634 DOI: 10.3389/fgene.2021.794105] [Reference Citation Analysis]
248 Finkelmeier F, Scheiner B, Leyh C, Best J, Fründt TW, Czauderna C, Beutel A, Bettinger D, Weiß J, Meischl T, Kütting F, Waldschmidt DT, Radu P, Schultheiß M, Peiffer KH, Ettrich TJ, Weinmann A, Wege H, Venerito M, Dufour JF, Lange CM, Pinter M, Waidmann O. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer 2021;10:360-9. [PMID: 34414123 DOI: 10.1159/000515490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
249 Kim KJ, Lee HW, Seong J. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol. 2020;. [PMID: 33217056 DOI: 10.1111/jgh.15319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
251 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Reference Citation Analysis]
252 Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, Brade A, Dinniwell R, Wong RKS, Cho C, Kim TK, Sapisochin G, Dawson LA. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120-126. [PMID: 33285195 DOI: 10.1016/j.radonc.2020.11.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
253 Ricke J, Steffen IG, Bargellini I, Berg T, Bilbao Jaureguizar JI, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Seidensticker M. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2020;2:100173. [PMID: 33103093 DOI: 10.1016/j.jhepr.2020.100173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
254 Tsilimigras DI, Hyer JM, Diaz A, Moris D, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC-0, A and B hepatocellular carcinoma. J Surg Oncol 2021;123:381-8. [PMID: 33174627 DOI: 10.1002/jso.26297] [Reference Citation Analysis]
255 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
256 Pereira RA, Pires ADRA, Echevarria A, Sousa-Pereira D, Noleto GR, Suter Correia Cadena SM. The toxicity of 1,3,4-thiadiazolium mesoionic derivatives on hepatocarcinoma cells (HepG2) is associated with mitochondrial dysfunction. Chem Biol Interact 2021;349:109675. [PMID: 34563518 DOI: 10.1016/j.cbi.2021.109675] [Reference Citation Analysis]
257 Yang JC, Hu JJ, Li YX, Luo W, Liu JZ, Ye DW. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Front Oncol 2022;12:781820. [PMID: 35211399 DOI: 10.3389/fonc.2022.781820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Lin L, Xiang X, Su S, Liu S, Xiong Y, Ma H, Yuan G, Nie D, Tang G. Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma. Front Chem 2021;9:630452. [PMID: 33937189 DOI: 10.3389/fchem.2021.630452] [Reference Citation Analysis]
259 Chen L, Wang Z, Song S, Sun T, Ren Y, Zhang W, Wang M, Liu Y, Zheng C. The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. J Oncol 2021;2021:5190611. [PMID: 34840570 DOI: 10.1155/2021/5190611] [Reference Citation Analysis]
260 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
261 Berardi G, Igarashi K, Li CJ, Ozaki T, Mishima K, Nakajima K, Honda M, Wakabayashi G. Parenchymal Sparing Anatomical Liver Resections With Full Laparoscopic Approach: Description of Technique and Short-term Results. Ann Surg 2021;273:785-91. [PMID: 31460879 DOI: 10.1097/SLA.0000000000003575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 16.0] [Reference Citation Analysis]
262 Delgado MG, Bosch J. HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Curr Hepatology Rep 2019;18:164-73. [DOI: 10.1007/s11901-019-00461-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
263 Buchanan R, Sinclair JMA. Alcohol use disorder and the liver. Addiction 2021;116:1270-8. [PMID: 32710592 DOI: 10.1111/add.15204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
264 Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, Kim KW, Lee SS. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Korean J Radiol 2020;21:280-9. [PMID: 32090520 DOI: 10.3348/kjr.2019.0447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
265 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
266 Vernuccio F, Porrello G, Cannella R, Vernuccio L, Midiri M, Giannitrapani L, Soresi M, Brancatelli G. Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. Clin Imaging 2021;70:33-45. [PMID: 33120287 DOI: 10.1016/j.clinimag.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Chazouillères O, Mallat A, Grangé J, Attali P, d'Alteroche L, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-khac E, Bernard-chabert B, Zucman D, Di Martino V, Sutton A, Pol S, Nahon P. Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status. Journal of Hepatology 2020;73:1434-45. [DOI: 10.1016/j.jhep.2020.05.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
268 Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways. Adv Pharm Bull 2020;10:648-55. [PMID: 33062605 DOI: 10.34172/apb.2020.078] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Lescure C, Estrade F, Pedrono M, Campillo-Gimenez B, Le Sourd S, Pracht M, Palard X, Bourien H, Muzellec L, Uguen T, Rolland Y, Garin E, Edeline J. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3794. [PMID: 34359695 DOI: 10.3390/cancers13153794] [Reference Citation Analysis]
270 Do HQ, Luong AB, Bonazza D, Bottin C, Doan TP, Tran LD, Truong NH, Tell G, Pham HL, Tiribelli C, Sukowati CH. Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma. Ann Hepatol 2020;19:645-52. [PMID: 32745631 DOI: 10.1016/j.aohep.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Sparchez Z, Mocan T, Hagiu C, Kacso G, Zaharie T, Rusu I, Al Hajjar N, Leucuta DC, Sparchez M. Real-Time Contrast-Enhanced-Guided Biopsy Compared with Conventional Ultrasound-Guided Biopsy in the Diagnosis of Hepatic Tumors on a Background of Advanced Chronic Liver Disease: A Prospective, Randomized, Clinical Trial. Ultrasound Med Biol 2019;45:2915-24. [PMID: 31447237 DOI: 10.1016/j.ultrasmedbio.2019.07.678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
272 Xiang YJ, Wang K, Zheng YT, Yu HM, Cheng YQ, Wang WJ, Shan YF, Cheng SQ. Prognostic Value of Microvascular Invasion in Eight Existing Staging Systems for Hepatocellular Carcinoma: A Bi-Centeric Retrospective Cohort Study. Front Oncol 2021;11:726569. [PMID: 34976789 DOI: 10.3389/fonc.2021.726569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Cai H, Ye BG, Ao JY, Zhu XD, Zhang YY, Chai ZT, Wang CH, Sun HC. High expression of S100A12 on intratumoral stroma cells indicates poor prognosis following surgical resection of hepatocellular carcinoma. Oncol Lett 2018;16:5398-404. [PMID: 30250610 DOI: 10.3892/ol.2018.9270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Pennisi G, Pipitone RM, Enea M, De Vincentis A, Battaglia S, Di Marco V, Di Martino V, Spatola F, Tavaglione F, Vespasiani-Gentilucci U, Zito R, Romeo S, Cammà C, Craxì A, Grimaudo S, Petta S. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2022. [PMID: 35146945 DOI: 10.1002/hep4.1877] [Reference Citation Analysis]
275 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
276 Schirmacher P. [Pathology of liver tumors]. Internist (Berl) 2020;61:131-9. [PMID: 31953548 DOI: 10.1007/s00108-019-00729-4] [Reference Citation Analysis]
277 Sun LY, Li ZL, Yang T. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue. Aliment Pharmacol Ther 2022;56:748-9. [PMID: 35879900 DOI: 10.1111/apt.17116] [Reference Citation Analysis]
278 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
279 Ou Q, Yu Y, Li A, Chen J, Yu T, Xu X, Xie X, Chen Y, Lin D, Zeng Q, Zhang Y, Tang X, Yao H, Luo B. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med 2020;8:230. [PMID: 32309377 DOI: 10.21037/atm.2020.01.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
280 An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B, Xie N. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett 2021;521:210-23. [PMID: 34428517 DOI: 10.1016/j.canlet.2021.08.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
281 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:974-83. [PMID: 31357028 DOI: 10.1016/j.cgh.2019.07.042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
283 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
284 Pereira Guedes T, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, Maia L, Moreira T, Manuel Ferreira J, Pedroto I. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. GE Port J Gastroenterol 2020;27:149-59. [PMID: 32509920 DOI: 10.1159/000503074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
285 Lu RC, She B, Gao WT, Ji YH, Xu DD, Wang QS, Wang SB. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019; 25(32): 4682-4695 [PMID: 31528094 DOI: 10.3748/wjg.v25.i32.4682] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
286 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
287 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
288 Renzulli M, Brandi N, Pecorelli A, Pastore LV, Granito A, Martinese G, Tovoli F, Simonetti M, Dajti E, Colecchia A, Golfieri R. Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. Diagnostics 2022;12:834. [DOI: 10.3390/diagnostics12040834] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Jadoul A, Bernard C, Lovinfosse P, Gérard L, Lilet H, Cornet O, Hustinx R. Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging 2020;47:828-37. [PMID: 31388721 DOI: 10.1007/s00259-019-04465-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
290 Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e28545. [PMID: 35089192 DOI: 10.1097/MD.0000000000028545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Zhu GQ, Liu WR, Tang Z, Qu WF, Fang Y, Jiang XF, Song SS, Wang H, Tao CY, Zhou PY, Huang R, Gao J, Sun HX, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Shi YH. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Mol Oncol 2021. [PMID: 34543520 DOI: 10.1002/1878-0261.13105] [Reference Citation Analysis]
292 Kimura T, Doi Y, Takahashi S, Kubo K, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Murakami Y, Kenjo M, Nagata Y. An overview of stereotactic body radiation therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:271-9. [PMID: 32223683 DOI: 10.1080/17474124.2020.1744434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Dou D, Zhang ZY, Wu ZY, Qiu XD, Zhong XG. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:5497041. [PMID: 32904600 DOI: 10.1155/2020/5497041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
294 Vidal-Cevallos P, Chavez-Tapia N. Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes? J Clin Transl Hepatol 2021;9:141-2. [PMID: 34007794 DOI: 10.14218/JCTH.2021.00137] [Reference Citation Analysis]
295 He F, Song K, Guan G, Huo J, Xin Y, Li T, Liu C, Zhu Q, Fan N, Guo Y, Wu L. The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:723-36. [PMID: 34188519 DOI: 10.2147/PGPM.S313848] [Reference Citation Analysis]
296 Zhang L, Makamure J, Zhao D, Liu Y, Guo X, Zheng C, Liang B. Bioinformatics analysis reveals meaningful markers and outcome predictors in HBV-associated hepatocellular carcinoma. Exp Ther Med 2020;20:427-35. [PMID: 32537007 DOI: 10.3892/etm.2020.8722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
297 Teh KK, Low AS, Chang JP, Tan CK. Masquerading Hypervascular Exophytic Liver Nodule. Eur J Case Rep Intern Med 2020;7:001840. [PMID: 33194859 DOI: 10.12890/2020_001840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
298 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
299 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
300 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
301 Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol (NY) 2022;47:1024-31. [PMID: 35020008 DOI: 10.1007/s00261-021-03403-2] [Reference Citation Analysis]
302 Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, Albadawi H, Oklu R. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med 2019;8:E55. [PMID: 30621040 DOI: 10.3390/jcm8010055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
303 Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, Lubel JS, Kronborg I, Arachchi N, Ryan M, Kemp WW, Knight V, Sundararajan V, Desmond P, Thompson AJ, Bell SJ. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust 2018;209:348-54. [PMID: 30309301 DOI: 10.5694/mja18.00373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
304 Hsieh YC, Limquiaco JL, Lin CC, Chen WT, Lin SM. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol (NY) 2019;44:1141-51. [PMID: 30460530 DOI: 10.1007/s00261-018-1831-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
305 Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633 [DOI: 10.4254/wjh.v14.i3.623] [Reference Citation Analysis]
306 Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J 2020;20:57-68. [PMID: 31611591 DOI: 10.1038/s41397-019-0106-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Liao H, Liao M, Xu L, Yan X, Ren B, Zhu Z, Yuan K, Zeng Y. Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma. EBioMedicine 2019;41:310-9. [PMID: 30665854 DOI: 10.1016/j.ebiom.2019.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
308 Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C; French-Italian-Belgium and Latin American collaborative group for HCC and liver transplantation. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Rep 2021;3:100331. [PMID: 34485882 DOI: 10.1016/j.jhepr.2021.100331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
309 Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)00350-0. [PMID: 34052255 DOI: 10.1016/j.jhep.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Ko SE, Lee MW, Rhim H, Kang TW, Song KD, Cha DI, Lim HK. Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma. Int J Hyperthermia 2020;37:1354-61. [PMID: 33297809 DOI: 10.1080/02656736.2020.1849824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Lee SH. Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective? Korean J Gastroenterol 2019;73:121-3. [PMID: 31013554 DOI: 10.4166/kjg.2019.73.3.121] [Reference Citation Analysis]
312 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Reference Citation Analysis]
313 Inzerillo A, Meloni MF, Taibbi A, Bartolotta TV. Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. World J Hepatol 2022; 14(5): 911-922 [DOI: 10.4254/wjh.v14.i5.911] [Reference Citation Analysis]
314 Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e2126992. [PMID: 34570206 DOI: 10.1001/jamanetworkopen.2021.26992] [Reference Citation Analysis]
315 Vietti Violi N, Fowler KJ, Sirlin CB, Taouli B. Abbreviated Magnetic Resonance Imaging for HCC Surveillance. Clin Liver Dis (Hoboken) 2021;17:133-8. [PMID: 33868653 DOI: 10.1002/cld.1016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
316 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 24.7] [Reference Citation Analysis]
317 Maheux A, Purcell Y, Harguem S, Vilgrain V, Ronot M. Targeted and non-targeted liver biopsies carry the same risk of complication. Eur Radiol 2019;29:5772-83. [DOI: 10.1007/s00330-019-06227-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
319 [DOI: 10.1101/2020.03.27.011841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Guo Y, Ren Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2022;22:270. [PMID: 35287627 DOI: 10.1186/s12885-022-09325-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Yoo J, Lee JM. Diagnostic Value of High Frame Rate Contrast-enhanced Ultrasonography and Post-processing Contrast Vector Imaging for Evaluation of Focal Liver Lesions: A Feasibility Study. Ultrasound Med Biol 2020;46:2254-64. [PMID: 32546409 DOI: 10.1016/j.ultrasmedbio.2020.05.001] [Reference Citation Analysis]
322 Thomas HR, Feng M. Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma. Curr Hepatology Rep 2021;20:12-22. [DOI: 10.1007/s11901-020-00559-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
323 Liu WR, Tian MX, Tao CY, Tang Z, Zhou YF, Song SS, Jiang XF, Wang H, Zhou PY, Qu WF, Fang Y, Ding ZB, Zhou J, Fan J, Shi YH. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer 2020;20:642. [PMID: 32650743 DOI: 10.1186/s12885-020-07138-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Wei J, Cui W, Fan W, Wang Y, Li J. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol 2020;10:1285. [PMID: 32850395 DOI: 10.3389/fonc.2020.01285] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
325 Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, Kang B, Kang MJ, Kim I, Cheon J, Hwang JE, Kang JH, Byeon S, Hong JY, Ryoo BY, Lim HY, Yoo C. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020;40:2544-2552. [PMID: 32563213 DOI: 10.1111/liv.14573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
326 Park S, Jung J, Cho B, Kim SY, Yun SC, Lim YS, Lee HC, Park J, Park JH, Kim JH, Yoon SM. In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy versus radiofrequency ablation. J Gastroenterol Hepatol 2020;35:2293. [PMID: 32909286 DOI: 10.1111/jgh.15250] [Reference Citation Analysis]
327 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Goh MJ, Kang W, Kim KM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol 2021;:1-8. [PMID: 34731072 DOI: 10.1080/00365521.2021.1988700] [Reference Citation Analysis]
329 Fernández-Varo G, Perramón M, Carvajal S, Oró D, Casals E, Boix L, Oller L, Macías-Muñoz L, Marfà S, Casals G, Morales-Ruiz M, Casado P, Cutillas PR, Bruix J, Navasa M, Fuster J, Garcia-Valdecasas JC, Pavel MC, Puntes V, Jiménez W. Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology 2020;72:1267-82. [PMID: 31961955 DOI: 10.1002/hep.31139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
330 Dong SY, Yang YT, Wang WT, Zhu S, Sun W, Zeng MS, Rao SX. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology. Acta Radiol 2022;63:734-42. [PMID: 33969700 DOI: 10.1177/02841851211014194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 European Association for the Study of the Liver. Electronic address: jhepatology@easloffice.eu., European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol 2022:S0168-8278(22)00326-9. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Reference Citation Analysis]
332 Bao M, Zhu Q, Aji T, Wei S, Tuergan T, Ha X, Tulahong A, Hu X, Hu Y. Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma. Front Oncol 2021;11:717826. [PMID: 34676160 DOI: 10.3389/fonc.2021.717826] [Reference Citation Analysis]
333 Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol 2022;12:822507. [DOI: 10.3389/fonc.2022.822507] [Reference Citation Analysis]
334 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
335 Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases. Radiology 2019;291:651-7. [PMID: 30990381 DOI: 10.1148/radiol.2019182587] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
336 Huang Q, Chen Y, Lin K, Sun C, Zheng S, Chen J, Wang Y, Zhou Y, Zhou W, Liu J, Zeng Y. Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study. Front Oncol 2021;11:673285. [PMID: 34722235 DOI: 10.3389/fonc.2021.673285] [Reference Citation Analysis]
337 Zhang S, Song W, Yang B, Jia H, Chen S, Li J, Yang C. A non-invasive model based on the virtual portal pressure gradient to predict the first variceal hemorrhage in cirrhotic patients. Hepatol Int 2022. [PMID: 35585289 DOI: 10.1007/s12072-022-10344-5] [Reference Citation Analysis]
338 Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, Shi H, Wang JG, Zhou J, Lu GD. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 2021;42:301-10. [PMID: 32699265 DOI: 10.1038/s41401-020-0478-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
339 Kairaluoma V, Karjalainen M, Pohjanen VM, Saarnio J, Niemelä J, Huhta H, Helminen O. Treatment trends and outcomes of hepatocellular carcinoma in a single center for 35 years. Minerva Surg 2021;76:252-63. [PMID: 33890436 DOI: 10.23736/S2724-5691.21.08426-1] [Reference Citation Analysis]
340 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
341 Ding DY, Liu L, Li HL, Gan XJ, Ding WB, Gu FM, Sun DP, Li W, Pan ZY, Yuan SX, Zhou WP. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00052-2. [PMID: 35428596 DOI: 10.1016/j.hbpd.2022.04.002] [Reference Citation Analysis]
342 Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatology Research 2021;51:461-71. [DOI: 10.1111/hepr.13595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
343 Ho SY, Hsu CY, Liu PH, Lee RC, Ko CC, Huang YH, Su CW, Hou MC, Huo TI. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Dig Dis Sci 2021;66:1730-8. [PMID: 32548811 DOI: 10.1007/s10620-020-06384-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
344 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
345 Akarca US, Akhan O, Bilgiç S, Bozkurt MF, Cantaşdemir M, Çermik TF, Çakaloğlu Y, Er Ö, Ilgıt E, Çapa Kaya G, Küçük NÖ, Numan F, Parıldar M, Türkmen C. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey. Diagn Interv Radiol 2021;27:732-9. [PMID: 34792027 DOI: 10.5152/dir.2021.201089] [Reference Citation Analysis]
346 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
347 Park HJ, Kim SY, Singal AG, Lee SJ, Won HJ, Byun JH, Choi SH, Yokoo T, Kim MJ, Lim YS. Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int 2021. [PMID: 34817921 DOI: 10.1111/liv.15110] [Reference Citation Analysis]
348 Sagar VM, Herring K, Curbishley S, Hodson J, Fletcher P, Karkhanis S, Mehrzad H, Punia P, Shah T, Shetty S, Ma YT. The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. Oncotarget 2021;12:2338-50. [PMID: 34853657 DOI: 10.18632/oncotarget.28136] [Reference Citation Analysis]
349 Cachay ER, Hadigan C, Mathews WC. Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. AIDS 2021;35:2211-3. [PMID: 34602589 DOI: 10.1097/QAD.0000000000003022] [Reference Citation Analysis]
350 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Front Oncol 2022;12:919824. [DOI: 10.3389/fonc.2022.919824] [Reference Citation Analysis]
352 Xu M, Xu D, Dong G, Ren Z, Zhang W, Aji T, Zhao Q, Chen X, Jiang T. The Safety and Efficacy of Nanosecond Pulsed Electric Field in Patients With Hepatocellular Carcinoma: A Prospective Phase 1 Clinical Study Protocol. Front Oncol 2022;12:869316. [DOI: 10.3389/fonc.2022.869316] [Reference Citation Analysis]
353 Zheng K, Liao A, Yan L, Yang J, Wen T, Wang W, Li B, Wu H, Jiang L. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 35441310 DOI: 10.1245/s10434-022-11757-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Wang P, Chen K. Gut microbiota and hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:345-7. [PMID: 32509825 DOI: 10.21037/hbsn.2019.10.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
355 Tiyarattanachai T, Fetzer DT, Kamaya A. Multicenter Study of ACR Ultrasound LI-RADS Visualization Scores on Serial Examinations: Implications for Changes in Surveillance Strategies. AJR Am J Roentgenol 2022. [PMID: 35383486 DOI: 10.2214/AJR.22.27405] [Reference Citation Analysis]
356 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
357 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
358 Sagawa T, Kogiso T, Sugiyama H, Hashimoto E, Yamamoto M, Tokushige K. Characteristics of hepatocellular carcinoma arising from Fontan‐associated liver disease. Hepatol Res 2020;50:853-62. [DOI: 10.1111/hepr.13500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
359 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
360 Ridder DA, Urbansky LL, Witzel HR, Schindeldecker M, Weinmann A, Berndt K, Gerber TS, Köhler BC, Nichetti F, Ludt A, Gehrke N, Schattenberg JM, Heinrich S, Roth W, Straub BK. Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers (Basel) 2022;14:430. [PMID: 35053591 DOI: 10.3390/cancers14020430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
362 van Oorschot E, Koc ÖM, Oude Lashof AM, van Loo IH, Ackens R, Posthouwer D, Koek GH. Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018. Journal of Virus Eradication 2022;8:100075. [DOI: 10.1016/j.jve.2022.100075] [Reference Citation Analysis]
363 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
364 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
365 Yao XS, Yan D, Jiang XX, Li X, Zeng HY, Li H. Short-term outcomes of radiofrequency ablation for hepatocellular carcinoma using cone-beam computed tomography for planning and image guidance. World J Clin Cases 2021; 9(7): 1580-1591 [PMID: 33728301 DOI: 10.12998/wjcc.v9.i7.1580] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Martí-Bonmatí L. Evidence levels in radiology: the insights into imaging approach. Insights Imaging 2021;12:45. [PMID: 33826000 DOI: 10.1186/s13244-021-00995-7] [Reference Citation Analysis]
367 Xiang YJ, Sun JX, Wu JY, Wang K, Feng JK, Wei YG, Zhou JY, Zhang ZB, Zhang YQ, Qin YY, Yan ML, Cheng SQ. Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. HPB (Oxford) 2022:S1365-182X(22)00102-2. [PMID: 35523655 DOI: 10.1016/j.hpb.2022.04.007] [Reference Citation Analysis]
368 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
369 Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol 2021;27:64-72. [PMID: 33723094 DOI: 10.4103/sjg.sjg_636_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
370 Tang J, Liu F, Yuan H, Li X, Tian X, Ji K, Li X, Wang W. Pretreatment Apparent Diffusion Coefficient as a Predictor of Response to Transcatheter Arterial Chemoembolization Immediately Combined with Radiofrequency Ablation for Treatment of Solitary Large Hepatocellular Carcinoma. Cancer Manag Res 2020;12:10127-38. [PMID: 33116868 DOI: 10.2147/CMAR.S270470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
371 Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K, Johnson PJ. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:359-70. [PMID: 32519782 DOI: 10.1111/apt.15825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
372 Zhang Y, Zhang MW, Fan XX, Mao DF, Ding QH, Zhuang LH, Lv SY. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(8): 355-368 [PMID: 32903981 DOI: 10.4240/wjgs.v12.i8.355] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
373 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
374 Di Sandro S, Danieli M, Ferla F, Lauterio A, De Carlis R, Benuzzi L, Buscemi V, Pezzoli I, De Carlis L. The current role of laparoscopic resection for HCC: a systematic review of past ten years. Transl Gastroenterol Hepatol 2018;3:68. [PMID: 30363804 DOI: 10.21037/tgh.2018.08.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
375 Raphael MJ, Karanicolas PJ. Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When? J Clin Oncol 2022;:JCO2102505. [PMID: 35649228 DOI: 10.1200/JCO.21.02505] [Reference Citation Analysis]
376 Scheiner B, Pinter M. Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?". J Hepatol 2022;76:988-9. [PMID: 34979133 DOI: 10.1016/j.jhep.2021.12.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
378 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Reference Citation Analysis]
379 Chen HY, Kee KM, Lu SN, Wang JH, Chen CH, Hung CH, Yen YH, Kuo YH. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. J Formos Med Assoc 2021:S0929-6646(21)00315-6. [PMID: 34303584 DOI: 10.1016/j.jfma.2021.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Zhu HB, Zheng ZY, Zhao H, Zhang J, Zhu H, Li YH, Dong ZY, Xiao LS, Kuang JJ, Zhang XL, Liu L. Radiomics-based nomogram using CT imaging for noninvasive preoperative prediction of early recurrence in patients with hepatocellular carcinoma.Diagn Interv Radiol. 2020;26:411-419. [PMID: 32490826 DOI: 10.5152/dir.2020.19623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
381 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
382 Li D, Yang ZY. Concerns Regarding Robotic vs Laparoscopic Right and Extended Right Hepatectomy. JAMA Surg 2022. [PMID: 35767268 DOI: 10.1001/jamasurg.2022.2239] [Reference Citation Analysis]
383 Ren Y, Cao Y, Ma H, Kan X, Zhou C, Liu J, Shi Q, Feng G, Xiong B, Zheng C. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer 2019;19:983. [PMID: 31640620 DOI: 10.1186/s12885-019-6237-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
384 Yu MQ, An TZ, Li JX, Chang DH, Zhang ZS, Xiao YD. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:1194-202. [PMID: 33819601 DOI: 10.1016/j.jvir.2021.03.540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Mendiratta-Lala M, Aslam A, Maturen KE, Westerhoff M, Sun Y, Maurino C, Parikh ND, Sonnenday CJ, Stein EB, Shampain KL, Kaza RK, Cuneo K, Masch W, Do RKG, Lawrence TS, Owen D. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02902-3. [PMID: 34644607 DOI: 10.1016/j.ijrobp.2021.10.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Kinoshita A, Hagiwara N, Osawa A, Akasu T, Matsumoto Y, Ueda K, Saeki C, Oikawa T, Koike K, Saruta M. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study. J Oncol Pharm Pract 2022;:10781552221077039. [PMID: 35112972 DOI: 10.1177/10781552221077039] [Reference Citation Analysis]
387 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
388 Park C, Chu HH, Kim JH, Kim SY, Alrashidi I, Gwon DI, Yoon HK, Kim N. Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. J Vasc Interv Radiol 2020;31:1998-2006.e1. [PMID: 32988715 DOI: 10.1016/j.jvir.2020.04.017] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
389 Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers (Basel) 2021;13:3455. [PMID: 34298669 DOI: 10.3390/cancers13143455] [Reference Citation Analysis]
390 Ma R, Zhao M, Zou X, Zhou J, Bai Z. MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? Oncol Lett 2021;21:324. [PMID: 33692856 DOI: 10.3892/ol.2021.12586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Neamatallah M, Serria MS, El‐bendary M, El‐gilany A, Alhawarey A, Abed S, Setate YA, Ammar OA. Association of Vitamin D Gene Polymorphisms With HCV Infection Outcome. Br J Biomed Sci 2022;79:10237. [DOI: 10.3389/bjbs.2021.10237] [Reference Citation Analysis]
392 Choe JW, Lee HY, Rim CH. Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis? World J Gastroenterol 2022; 28(7): 704-714 [DOI: 10.3748/wjg.v28.i7.704] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Wang CL, Hou MC, Huo TI. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scand J Gastroenterol 2022;:1-9. [PMID: 35830511 DOI: 10.1080/00365521.2022.2098052] [Reference Citation Analysis]
394 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
395 Weiss CR, Nezami N. One Step Closer to Precision Medicine for Transarterial Therapy of HCC. Radiology 2020;297:235-6. [PMID: 32804050 DOI: 10.1148/radiol.2020202843] [Reference Citation Analysis]
396 Franck M, Thon C, Schütte K, Malfertheiner P, Link A. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World J Hepatol 2020; 12(11): 1031-1045 [PMID: 33312427 DOI: 10.4254/wjh.v12.i11.1031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
397 Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology 2022;29:3259-71. [DOI: 10.3390/curroncol29050266] [Reference Citation Analysis]
398 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022;14:3332. [DOI: 10.3390/cancers14143332] [Reference Citation Analysis]
400 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
401 Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN, Kuo YH. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci 2021. [PMID: 34166565 DOI: 10.1002/kjm2.12413] [Reference Citation Analysis]
402 Huang RJ, Sharp N, Talamoa R, Kapphahn K, Sathye V, Lin B, Srinivasan M, Palaniappan LP. Disaggregated mortality from gastrointestinal cancers in Asian Americans: Analysis of United States death records. Int J Cancer 2021;148:2954-63. [PMID: 33527405 DOI: 10.1002/ijc.33490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Maesaka K, Sakamori R, Yamada R, Tahata Y, Urabe A, Shigekawa M, Kodama T, Hikita H, Tatsumi T, Takehara T. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res 2020;50:365-73. [PMID: 31661722 DOI: 10.1111/hepr.13446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
404 Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M, Zhang X, Chen Y, Ma C, Ge H, Wang J, Wu J, Wei T, Chen Q, Wu J, Yu C, Xiao Y, Feng X, Guo G, Liang T, Bai X. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut 2019;68:2019-31. [PMID: 31227589 DOI: 10.1136/gutjnl-2019-318912] [Cited by in Crossref: 115] [Cited by in F6Publishing: 89] [Article Influence: 38.3] [Reference Citation Analysis]
405 Bliemsrieder E, Kaissis G, Grashei M, Topping G, Altomonte J, Hundshammer C, Lohöfer F, Heid I, Keim D, Gebrekidan S, Trajkovic-Arsic M, Winkelkotte AM, Steiger K, Nawroth R, Siveke J, Schwaiger M, Makowski M, Schilling F, Braren R. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC. Sci Rep 2021;11:1191. [PMID: 33441943 DOI: 10.1038/s41598-020-80952-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
406 Bauer U, Gerum S, Roeder F, Münch S, Combs SE, Philipp AB, De Toni EN, Kirstein MM, Vogel A, Mogler C, Haller B, Neumann J, Braren RF, Makowski MR, Paprottka P, Guba M, Geisler F, Schmid RM, Umgelter A, Ehmer U. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. World J Gastroenterol 2021; 27(24): 3630-3642 [PMID: 34239274 DOI: 10.3748/wjg.v27.i24.3630] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Olson MC, Vietti Violi N, Taouli B, Venkatesh SK. Abbreviated Magnetic Resonance Imaging Protocols in the Abdomen and Pelvis. Magn Reson Imaging Clin N Am 2020;28:381-94. [PMID: 32624156 DOI: 10.1016/j.mric.2020.03.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
408 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T, Oku Y, Kimura Y, Nakamura N. Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma. Acta Oncol 2022;61:104-10. [PMID: 34788194 DOI: 10.1080/0284186X.2021.2001566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
410 Mahn R, Sadeghlar F, Bartels A, Zhou T, Weismüller T, Kupczyk P, Meyer C, Gaertner FC, Toma M, Vilz T, Knipper P, Glowka T, Manekeller S, Kalff J, Strassburg CP, Gonzalez-Carmona MA. Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes. Medicine (Baltimore) 2021;100:e27082. [PMID: 34559100 DOI: 10.1097/MD.0000000000027082] [Reference Citation Analysis]
411 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
413 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
414 Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol 2022;76:1348-61. [PMID: 35589255 DOI: 10.1016/j.jhep.2022.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Wang H, Qian Y, Wu M, Cong W. Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg 2020;24:2737-47. [DOI: 10.1007/s11605-019-04251-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
418 Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med 2021;62:1235-41. [PMID: 33509970 DOI: 10.2967/jnumed.120.257915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
419 Kim DH, Kim B, Youn SY, Kim H, Choi JI. Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1763. [PMID: 34679461 DOI: 10.3390/diagnostics11101763] [Reference Citation Analysis]
420 Karakousis ND, Papatheodoridi A, Chatzigeorgiou A, Papatheodoridis G. Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link. Liver Int 2020;40:2917-27. [PMID: 32890439 DOI: 10.1111/liv.14659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
421 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J;  European Hepatocellular Cancer Liver Transplant Study Group. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl. 2019;25:1023-1033. [PMID: 31087772 DOI: 10.1002/lt.25492] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
422 Hu K, Lu S, Li M, Zhang F, Tang B, Yuan J, Shan Y, Xu P, Chen R, Ren Z, Yin X. A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. J Cancer 2020;11:4589-96. [PMID: 32489476 DOI: 10.7150/jca.44847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
423 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Zhu HD, Li X, Ji JS, Huang M, Shao GL, Lu J, Zhao XY, Li HL, Yang ZQ, Tu JF, Zhou JM, Zeng CH, Teng GJ. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. Eur Radiol 2022. [PMID: 35776182 DOI: 10.1007/s00330-022-08848-7] [Reference Citation Analysis]
425 Otto G, Pitton MB, Hoppe-Lotichius M, Weinmann A. Liver transplantation and BCLC classification: Limitations impede optimum treatment. Hepatobiliary Pancreat Dis Int 2021;20:6-12. [PMID: 33349607 DOI: 10.1016/j.hbpd.2020.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
426 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Kudo M. Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer. 2018;7:215-224. [PMID: 30319981 DOI: 10.1159/000492533] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
428 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
429 Kang HJ, Lee JM, Yoon JH, Han JK. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. Korean J Radiol 2021;22:354-65. [PMID: 33236540 DOI: 10.3348/kjr.2020.0973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
430 Jia KF, Wang H, Yu CL, Yin WL, Zhang XD, Wang F, Sun C, Shen W. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00015-7. [PMID: 35260337 DOI: 10.1016/j.hbpd.2022.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Liao H, Long Y, Han R, Wang W, Xu L, Liao M, Zhang Z, Wu Z, Shang X, Li X, Peng J, Yuan K, Zeng Y. Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma. Clin Transl Med 2020;10:e102. [PMID: 32536036 DOI: 10.1002/ctm2.102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
432 Luo HL, Luo T, Liu JJ, Wu FX, Bai T, Ou C, Chen J, Li LQ, Zhong JH. Macrophage polarization-associated lnc-Ma301 interacts with caprin-1 to inhibit hepatocellular carcinoma metastasis through the Akt/Erk1 pathway. Cancer Cell Int 2021;21:422. [PMID: 34376192 DOI: 10.1186/s12935-021-02133-1] [Reference Citation Analysis]
433 Ah Hwang J, Wook Kang T, Hye Min J, Kon Kim Y, Hyun Kim S, Hyun Sinn D, Kim K. Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110328] [Reference Citation Analysis]
434 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
435 Sansone V, Tovoli F, Casadei-Gardini A, Di Costanzo GG, Magini G, Sacco R, Pressiani T, Trevisani F, Rimini M, Tortora R, Nardi E, Ielasi L, Piscaglia F, Granito A. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clin Transl Gastroenterol 2021;12:e00286. [PMID: 33443944 DOI: 10.14309/ctg.0000000000000286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
436 Lee DH. Recent technical advances in radiofrequency ablations for hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:169-74. [DOI: 10.18528/ijgii210050] [Reference Citation Analysis]
437 Shiha G, Soliman R, Mikhail N, Hassan A, Eslam M. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. Liver Int 2021. [PMID: 34174150 DOI: 10.1111/liv.14995] [Reference Citation Analysis]
438 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
439 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
440 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
441 Wang W, Zhang JC, Tian WS, Chen LD, Zheng Q, Hu HT, Wu SS, Guo Y, Xie XY, Lu MD, Kuang M, Liu LZ, Ruan SM. Shear wave elastography-based ultrasomics: differentiating malignant from benign focal liver lesions. Abdom Radiol (NY) 2021;46:237-48. [PMID: 32564210 DOI: 10.1007/s00261-020-02614-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
442 Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clin Res Hepatol Gastroenterol 2021;45:101731. [PMID: 34139320 DOI: 10.1016/j.clinre.2021.101731] [Reference Citation Analysis]
443 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
444 Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993 [DOI: 10.3748/wjg.v28.i29.3981] [Reference Citation Analysis]
445 Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, Hiraoka A, Huo T, Liu P, Johnson PJ, Roberts SK. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00832-0] [Reference Citation Analysis]
446 Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14:1747. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Reference Citation Analysis]
447 Liu HY, Lee Y, McLean K, Leggett D, Hodgkinson P, Fawcett J, Mott R, Stuart K, Pryor D. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service. Clin Oncol (R Coll Radiol) 2020;32:e194-202. [PMID: 32345457 DOI: 10.1016/j.clon.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
448 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
449 Lee S, Kim KW, Jeong WK, Jeong SY, Hwang JA, Choi JS, Lee SG, Joh JW. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study. Ann Surg Oncol 2021. [PMID: 33751296 DOI: 10.1245/s10434-021-09772-8] [Reference Citation Analysis]
450 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
451 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
452 Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O. Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. J Viral Hepat 2021;28:1177-89. [PMID: 34003542 DOI: 10.1111/jvh.13545] [Reference Citation Analysis]
453 Zhou PY, Yang CP, Tang Z, Yi Y, Liu WR, Tian MX, Huang JL, Gan W, Jiang XF, Liu G, Wang H, Tao CY, Fang Y, Qu WF, Zhou C, Guan RY, Sun BY, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Gong GZ, Shi YH, Qiu SJ. Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging (Albany NY). 2019;11:11111-11123. [PMID: 31829979 DOI: 10.18632/aging.102513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
454 Ismael MN, Forde J, Milla E, Khan W, Cabrera R. Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation. Biomed Res Int 2019;2019:7284040. [PMID: 31737675 DOI: 10.1155/2019/7284040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
455 Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:649. [PMID: 35158917 DOI: 10.3390/cancers14030649] [Reference Citation Analysis]
456 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
457 Nakamura H, Tanaka S, Miyanishi K, Kawano Y, Osuga T, Ishikawa K, Yoshida M, Ohnuma H, Murase K, Takada K, Yamaguchi H, Nagayama M, Kimura Y, Takemasa I, Kato J. A case of hypervascular tumors in the liver and pancreas: synchronous hepatocellular carcinoma and pancreatic metastasis from renal cell carcinoma 36 years after nephrectomy.Clin Case Rep. 2021;9:932-937. [PMID: 33598275 DOI: 10.1002/ccr3.3691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
458 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
459 Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (NY) 2021;46:2839-49. [PMID: 33388805 DOI: 10.1007/s00261-020-02884-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
460 Sarcognato S, García-Lezana T, Villanueva A. Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:62-5. [PMID: 31508222 DOI: 10.1002/cld.810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
461 Lee SU, Yoon SM, Cheng JC, Kim TH, Kim BH, Park JH, Jung J, Tsai CL, Chiang Y, Park JW. Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Front Oncol 2021;11:646473. [PMID: 33718247 DOI: 10.3389/fonc.2021.646473] [Reference Citation Analysis]
462 He X, Peng Y, Zhou Z, Li W. Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review. Front Oncol 2022;12:784224. [PMID: 35372050 DOI: 10.3389/fonc.2022.784224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Nenu I, Breaban I, Pascalau S, Bora CN, Stefanescu H. The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Transl Cancer Res 2019;8:S261-74. [PMID: 35117106 DOI: 10.21037/tcr.2018.11.23] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
465 Krause J, von Felden J, Casar C, Fründt TW, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann SA, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse AW, Wege H, Schulze K. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. BMC Cancer 2020;20:1130. [PMID: 33225916 DOI: 10.1186/s12885-020-07580-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
466 Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, Li M, Chen S, Fang W, Dong L, Xuan S, He T, Cao B, Lu Y. In situ Thermal-Responsive Magnetic Hydrogel for Multidisciplinary Therapy of Hepatocellular Carcinoma. Nano Lett . [DOI: 10.1021/acs.nanolett.1c04413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
467 Iliescu L, Toma L, Mercan-Stanciu A, Grumeza M, Ioanitescu S. Contrast-Enhanced Ultrasonography in the Diagnosis of Portal Vein Thrombosis: A Pictorial Review. Ultrasound Q. 2019;35:311-315. [PMID: 31083039 DOI: 10.1097/ruq.0000000000000451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
468 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
470 Urban SK, Sänger H, Krawczyk M, Julich-Haertel H, Willms A, Ligocka J, Azkargorta M, Mocan T, Kahlert C, Kruk B, Jankowski K, Patkowski W, Krawczyk M, Zieniewicz K, Hołówko W, Krupa Ł, Rzucidło M, Gutkowski K, Wystrychowski W, Król R, Raszeja-Wyszomirska J, Słomka A, Schwab R, Wöhler A, Gonzalez-Carmona MA, Gehlert S, Sparchez Z, Banales JM, Strassburg CP, Lammert F, Milkiewicz P, Kornek M. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver Int 2020;40:3103-16. [PMID: 32614460 DOI: 10.1111/liv.14585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
471 Kim JH, Kang SH, Lee M, Choi HS, Jun BG, Kim TS, Choi DH, Suk KT, Kim MY, Kim YD, Cheon GJ, Baik SK, Kim DJ. Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study. J Gastroenterol Hepatol 2020;35:1795-803. [PMID: 32222111 DOI: 10.1111/jgh.15046] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
472 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
473 Park C, Kim JH, Kim PH, Kim SY, Gwon DI, Chu HH, Park M, Hur J, Kim JY, Kim DJ. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol 2021;22:213-24. [PMID: 32901464 DOI: 10.3348/kjr.2020.0325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
474 Zhang Y, Chen H, Chen S, Li W. Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis. Int J Hyperthermia 2021;38:1052-9. [PMID: 34251953 DOI: 10.1080/02656736.2021.1947529] [Reference Citation Analysis]
475 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
476 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Reference Citation Analysis]
477 Ai J, Gong C, Wu J, Gao J, Liu W, Liao W, Wu L. MicroRNA‑181c suppresses growth and metastasis of hepatocellular carcinoma by modulating NCAPG. Cancer Manag Res 2019;11:3455-67. [PMID: 31114379 DOI: 10.2147/CMAR.S197716] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
478 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
479 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
480 Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019;116:56-66. [PMID: 31173963 DOI: 10.1016/j.ejca.2019.04.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
481 Yoshino K, Yoh T, Taura K, Seo S, Ciria R, Briceño-Delgado J. A systematic review of prediction models for post-hepatectomy liver failure in patients undergoing liver surgery. HPB (Oxford) 2021:S1365-182X(21)00141-6. [PMID: 34090805 DOI: 10.1016/j.hpb.2021.05.002] [Reference Citation Analysis]
482 Smolock AR, Shaw C. Hepatic Microwave Ablation in Challenging Locations. Semin Intervent Radiol 2019;36:392-7. [PMID: 31798213 DOI: 10.1055/s-0039-1697003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
483 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
485 Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. J Hep Reports. 2019;1:114-119. [PMID: 32039359 DOI: 10.1016/j.jhepr.2019.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
486 Díaz-González Á, Vilana R, Bianchi L, García-Criado Á, Rimola J, Rodríguez de Lope C, Ferrer J, Ayuso C, Da Fonseca LG, Reig M, Forner A. Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. J Vasc Interv Radiol 2020;31:710-9. [PMID: 31685360 DOI: 10.1016/j.jvir.2019.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
487 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
488 Auer TA, Sofue K, Ueshima E, Rauer N, Yamaguchi T, Gebauer B, Hamm B, Murakami T, Althoff C. Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. JHC 2022;Volume 9:695-705. [DOI: 10.2147/jhc.s359705] [Reference Citation Analysis]
489 Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol 2020;18:119. [PMID: 32487104 DOI: 10.1186/s12957-020-01887-8] [Reference Citation Analysis]
490 Singal AG, Ioannou GN. For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective? Clin Gastroenterol Hepatol 2019;17:1732-5. [PMID: 30772587 DOI: 10.1016/j.cgh.2019.02.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
491 Ruiz E, Pineau P, Flores C, Fernández R, Cano L, Cerapio JP, Casavilca-Zambrano S, Berrospi F, Chávez I, Roche B, Bertani S. A preoperative nomogram for predicting long-term survival after resection of large hepatocellular carcinoma (>10 cm). HPB (Oxford) 2021:S1365-182X(21)00177-5. [PMID: 34226129 DOI: 10.1016/j.hpb.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
492 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
493 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
494 Ahn JC, Lauzon M, Luu M, Friedman ML, Kosari K, Nissen N, Lu SC, Roberts LR, Singal AG, Yang JD. Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: Analysis of the US National Cancer Database. J Nucl Med 2021:jnumed. [PMID: 33837067 DOI: 10.2967/jnumed.121.261954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
495 Mao X, Guo Y, Wen F, Liang H, Sun W, Lu Z. Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE). Cancer Imaging 2021;21:49. [PMID: 34384496 DOI: 10.1186/s40644-021-00418-2] [Reference Citation Analysis]
496 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
497 Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Olveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int 2021;41:2885-91. [PMID: 34392590 DOI: 10.1111/liv.15032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
498 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
499 Lee S, Kim M, Kim S, Shin H, Kim DY, Choi J, Park M, Mitchell DG. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 2020;14:70-9. [DOI: 10.1007/s12072-019-10002-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
500 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Reference Citation Analysis]
501 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
502 Ronot M. Performance of LI-RADS for the Noninvasive Diagnosis of HCC: Pathology Should Not Be the Only Acceptable Reference. Radiology 2022;:213224. [PMID: 35230189 DOI: 10.1148/radiol.213224] [Reference Citation Analysis]
503 Cabibbo G, Celsa C, Cammà C, Craxì A. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? Liver Int 2018;38:2108-16. [PMID: 29935096 DOI: 10.1111/liv.13918] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
504 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
505 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
506 Li L, Xu L, Zhou S, Wang P, Zhang M, Li B. Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis. BMC Surg 2022;22:104. [PMID: 35313888 DOI: 10.1186/s12893-022-01564-5] [Reference Citation Analysis]
507 Meng D, Liang C, Zheng Y, Wang X, Liu K, Lin Z, Zhu Q, Zhao X. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients. Eur Radiol 2022. [PMID: 35639146 DOI: 10.1007/s00330-022-08874-5] [Reference Citation Analysis]
508 Zheng X, Ren Y, Hu H, Qian K. Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma After Curative Resection: A 10-Year Single-Center Comparative Study. Front Oncol 2021;11:713432. [PMID: 34568043 DOI: 10.3389/fonc.2021.713432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
510 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
511 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
512 Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surg 2021;21:178. [PMID: 33794850 DOI: 10.1186/s12893-021-01180-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J 2021. [PMID: 34918471 DOI: 10.1002/ueg2.12188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
514 Boldrini L, Corradini S, Gani C, Henke L, Hosni A, Romano A, Dawson L. MR-Guided Radiotherapy for Liver Malignancies. Front Oncol 2021;11:616027. [PMID: 33869001 DOI: 10.3389/fonc.2021.616027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
515 Meyer T, Johnson P. Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. J Hepatol 2019;70:1060-1. [PMID: 30943424 DOI: 10.1016/j.jhep.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
516 El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25(14): 1653-1665 [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
517 Chen L, Ke Z, Xiong F, Kan X, Ren Y, Cao Y, Sun T, Yan L, Zhou G, Zheng C. Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma. Anticancer Drugs 2020;31:966-72. [PMID: 31977568 DOI: 10.1097/CAD.0000000000000913] [Reference Citation Analysis]
518 Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
519 Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 2019;8:505-19. [PMID: 31799207 DOI: 10.1159/000503032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
520 Ghoneim S, Butt MU, Trujillo S, Asaad I. FIB-4 Regression With Direct-Acting Antiviral Therapy in Patients With Hepatitis C Infection: A Safety-Net Hospital Experience. Front Med (Lausanne) 2020;7:359. [PMID: 32793612 DOI: 10.3389/fmed.2020.00359] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
522 Yang YL, Tsai MC, Chang YH, Wang CC, Chu PY, Lin HY, Huang YH. MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA. Int J Mol Sci 2021;22:6001. [PMID: 34206143 DOI: 10.3390/ijms22116001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Li L, Xin Y, Zhang X, Chen Y, Yang Y, Zhou X, Ye F. The effectiveness of Radiofrequency Ablation for Patients with BCLC B1 Stage Hepatocellular Carcinoma downgraded by Transarterial Chemoembolization. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101878] [Reference Citation Analysis]
524 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
526 de Nucci G, Della Corte C, Reati R, Imperatore N, Arena I, Larghi A, Manes G. Endoscopic ultrasound-guided radiofrequency ablation for hepatocellular carcinoma in cirrhosis: a case report test for efficacy and future perspectives. Endosc Int Open. 2020;8:E1713-E1716. [PMID: 33140029 DOI: 10.1055/a-1236-3105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Lyu N, Kong Y, Pan T, Mu L, Sun X, Li S, Deng H, Lai J, Zhao M. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia 2019;36:1002-10. [DOI: 10.1080/02656736.2019.1663279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
528 Kim M, Lee S, An C. Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma. Eur Radiol 2019;29:5101-10. [DOI: 10.1007/s00330-019-06030-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
529 Serenari M, Prosperi E, Allard MA, Paterno M, Golse N, Laurenzi A, Adam R, Ravaioli M, Cherqui D, Cescon M. The Impact of Time Interval between Hepatic Resection and Liver Transplantation on Clinical Outcome in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2398. [PMID: 34063501 DOI: 10.3390/cancers13102398] [Reference Citation Analysis]
530 Li B, Ge YZ, Yan WW, Gong B, Cao K, Zhao R, Li C, Zhang YW, Jiang YH, Zuo S. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway. Cell Prolif 2022;:e13273. [PMID: 35748106 DOI: 10.1111/cpr.13273] [Reference Citation Analysis]
531 Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, IJzermans JNM, Koerkamp BG. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol 2021:S0748-7983(21)00738-1. [PMID: 34602315 DOI: 10.1016/j.ejso.2021.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
532 Vilgrain V, Raynaud L, Paulatto L, Ronot M. Imaging of liver tumours: What’s new? Liver Int 2020;40:154-9. [DOI: 10.1111/liv.14353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
534 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
535 Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Reference Citation Analysis]
536 Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q, Lai J, Chen M, Zhao M. Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients? J Hepatocell Carcinoma 2020;7:377-84. [PMID: 33365285 DOI: 10.2147/JHC.S287641] [Reference Citation Analysis]
537 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 2019;19:1088. [PMID: 31718608 DOI: 10.1186/s12885-019-6322-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
539 Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:882-888. [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
540 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
541 Lin M, Lu DS, Duan Y, Liao P, Sayre J, Xie X, Kuang M. Cirrhotic Nodule Transformation to Hepatocellular Carcinoma: Natural History and Predictive Biomarkers on Contrast-Enhanced Ultrasound. AJR Am J Roentgenol 2020;214:96-104. [PMID: 31642698 DOI: 10.2214/AJR.19.21739] [Reference Citation Analysis]
542 Ichikawa S, Motosugi U, Enomoto N, Onishi H. Magnetic resonance elastography can predict development of hepatocellular carcinoma with longitudinally acquired two-point data. Eur Radiol 2019;29:1013-21. [DOI: 10.1007/s00330-018-5640-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
543 Park J, Park JW, Kang MK. Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Yeungnam Univ J Med 2019;36:192-200. [PMID: 31620633 DOI: 10.12701/yujm.2019.00269] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Miyata T, Matsumoto T, Nakao Y, Higashi T, Imai K, Hayashi H, Nitta H, Chikamoto A, Beppu T, Yamashita YI, Baba H. Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbecks Arch Surg 2022. [PMID: 35441947 DOI: 10.1007/s00423-022-02513-9] [Reference Citation Analysis]
545 Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021;74:2342-52. [PMID: 33739462 DOI: 10.1002/hep.31819] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 50.0] [Reference Citation Analysis]
546 Mo Q, Liu Y, Zhou Z, Li R, Gong W, Xiang B, Tang W, Yu H. Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. Front Oncol 2022;12:876900. [PMID: 35664791 DOI: 10.3389/fonc.2022.876900] [Reference Citation Analysis]
547 Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES, Bae SH, Choi JY, Yoon SK. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer 2020;8:e000301. [PMID: 32221015 DOI: 10.1136/jitc-2019-000301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
548 Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Marco MD, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of Atezolizumab-Bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Dig Liver Dis 2022:S1590-8658(22)00587-4. [PMID: 35906166 DOI: 10.1016/j.dld.2022.07.003] [Reference Citation Analysis]
549 Yoh T, Seo S, Taura K, Hamaguchi Y, Ogiso S, Fukumitsu K, Ishii T, Hata K, Kaido T, Nakamoto Y, Uemoto S. Identifying Patients Who May Benefit from Liver Resection Compared to Living Donor Liver Transplantation for Hepatocellular Carcinoma Using 18F-FDG PET. World J Surg 2021. [PMID: 34274984 DOI: 10.1007/s00268-021-06235-9] [Reference Citation Analysis]
550 Liu B, Huang G, Xie X, Zhao Q, Su L, Liu M, Li X, Long J, Kuang M, Xie X. Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience. International Journal of Hyperthermia 2020;37:1202-9. [DOI: 10.1080/02656736.2020.1834154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Ding WZ, Liu S, Liu F, Cheng Z, Yu X, Han ZY, Yu J, Liang P. Are all local tumour progressions of HCC related to thermal ablation? A study of the causes and classification of local tumour progression. Eur Radiol 2022. [PMID: 35704110 DOI: 10.1007/s00330-022-08913-1] [Reference Citation Analysis]
552 Wang XD, Peng JB, Zhou CY, Que Q, Li HY, He Y, Yang H. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncol Rep 2020;43:1915-27. [PMID: 32186781 DOI: 10.3892/or.2020.7545] [Reference Citation Analysis]
553 Lerut J, Iesari S. Vascular tumours of the liver: a particular story. Transl Gastroenterol Hepatol. 2018;3:62. [PMID: 30363746 DOI: 10.21037/tgh.2018.09.02] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
554 Cao F, Yang Y, Si T, Luo J, Zeng H, Zhang Z, Feng D, Chen Y, Zheng J. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Front Oncol 2021;11:783480. [PMID: 34988019 DOI: 10.3389/fonc.2021.783480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
555 An J, Kim D, Oh B, Oh YJ, Song J, Park N, Kim HI, Kang HJ, Oh JH, Kim W, Lee E, Sung CO, Song GW, Kim DG, Yu E, Letouzé E, Zucman-Rossi J, Lee HC, Shim JH. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. Hepatology 2022;75:997-1011. [PMID: 34478159 DOI: 10.1002/hep.32135] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
556 Devan AR, Kumar AR, Nair B, Anto NP, Muraleedharan A, Mathew B, Kim H, Nath LR. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals (Basel) 2021;14:656. [PMID: 34358082 DOI: 10.3390/ph14070656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
557 Deng S, Solinas A, Calvisi DF. Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Front Oncol 2021;11:756672. [PMID: 34722310 DOI: 10.3389/fonc.2021.756672] [Reference Citation Analysis]
558 Trotovšek B, Djokić M, Čemažar M, Serša G. New era of electrochemotherapy in treatment of liver tumors in conjunction with immunotherapies. World J Gastroenterol 2021; 27(48): 8216-8226 [DOI: 10.3748/wjg.v27.i48.8216] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
559 Pace C, Nardone V, Roma S, Chegai F, Toti L, Manzia TM, Tisone G, Orlacchio A. Evaluation of Contrast-Enhanced Intraoperative Ultrasound in the Detection and Management of Liver Lesions in Patients with Hepatocellular Carcinoma. J Oncol 2019;2019:6089340. [PMID: 31467539 DOI: 10.1155/2019/6089340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
560 Tsilimigras DI, Pawlik TM. ASO Author Reflections: Recurrence Patterns and Outcomes After Resection of Hepatocellular Carcinoma Within and Beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020;27:2332-3. [PMID: 32297083 DOI: 10.1245/s10434-020-08455-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
561 Nguyen N, Rode A, Trillaud H, Aubé C, Manichon AF, Hocquelet A, Paisant A, Dao T, Nahon P, Ganne-Carrié N, Blaise L, Cauchy F, Sutter O, Séror O, Nault JC. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34894060 DOI: 10.1111/liv.15129] [Reference Citation Analysis]
562 Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 2021;56:181-90. [PMID: 33392749 DOI: 10.1007/s00535-020-01753-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
563 Erkan B, Meier J, Clark TJ, Kaplan J, Lambert JR, Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC. PLoS One 2019;14:e0226291. [PMID: 31821360 DOI: 10.1371/journal.pone.0226291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
564 Ruan SM, Zheng Q, Wang Z, Hu HT, Chen LD, Guo HL, Xie XY, Lu MD, Li W, Wang W. Comparison of Real-Time Two-Dimensional and Three-Dimensional Contrast-Enhanced Ultrasound to Quantify Flow in an In Vitro Model: A Feasibility Study. Med Sci Monit 2019;25:10029-35. [PMID: 31879414 DOI: 10.12659/MSM.919160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
565 Yan B, Li T, Shen L, Zhou Z, Liu X, Wang X, Sun X. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Biochem Biophys Res Commun 2019;515:275-81. [PMID: 31146919 DOI: 10.1016/j.bbrc.2019.05.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
566 Benedetti Cacciaguerra A, Görgec B, Lanari J, Cipriani F, Russolillo N, Mocchegiani F, Zimmitti G, Alseidi A, Ruzzenente A, Edwin B, D'Hondt M, Besselink MG, Giuliante F, Fuks D, Rotellar F, López-Ben S, Ferrero A, Aldrighetti L, Cillo U, Vivarelli M, Abu Hilal M. Outcome of major hepatectomy in cirrhotic patients; does surgical approach matter? A propensity score matched analysis. J Hepatobiliary Pancreat Sci 2021. [PMID: 34855277 DOI: 10.1002/jhbp.1087] [Reference Citation Analysis]
567 El Mahdy HA, Abdelhamid IA, Amen AI, Abdelsameea E, Hassouna MM. MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2019;20:2723-31. [PMID: 31554369 DOI: 10.31557/APJCP.2019.20.9.2723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
568 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
569 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
570 De Toni EN. Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut 2020;69:1887-8. [PMID: 31611301 DOI: 10.1136/gutjnl-2019-319658] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
571 Canillas L, Parcerisa M, Coll S, García-retortillo M, Macià F, Bessa X, Castells X, Puigvehí M, Posso M. Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital. Cancer Epidemiology 2022;78:102142. [DOI: 10.1016/j.canep.2022.102142] [Reference Citation Analysis]
572 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 114] [Cited by in F6Publishing: 80] [Article Influence: 114.0] [Reference Citation Analysis]
573 Mcpherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, Mccallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00061-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
574 Renzulli M, Peta G, Vasuri F, Marasco G, Caretti D, Bartalena L, Spinelli D, Giampalma E, D'Errico A, Golfieri R. Standardization of conventional chemoembolization for hepatocellular carcinoma. Ann Hepatol 2021;22:100278. [PMID: 33129978 DOI: 10.1016/j.aohep.2020.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
575 Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World J Gastroenterol 2022; 28(21): 2361-2382 [DOI: 10.3748/wjg.v28.i21.2361] [Reference Citation Analysis]
576 Zhang X, He X, Zeng Q, Tan L, Xu E, Li K, Zheng R. Utility of Fusion Imaging for Percutaneous Thermal Ablation of Hepatocellular Carcinoma in the Caudate Lobe. J Vasc Interv Radiol 2021;32:1209-14. [PMID: 34015488 DOI: 10.1016/j.jvir.2021.04.028] [Reference Citation Analysis]
577 Sawatzki M, Güller U, Güsewell S, Husarik DB, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. J Hepatol 2021;74:419-27. [PMID: 33065168 DOI: 10.1016/j.jhep.2020.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
578 Zeng J, Zeng J, Wu Q, Lin K, Zeng J, Guo P, Zhou W, Liu J. Novel inflammation-based prognostic nomograms for individualized prediction in hepatocellular carcinoma after radical resection. Ann Transl Med 2020;8:1061. [PMID: 33145280 DOI: 10.21037/atm-20-1919] [Reference Citation Analysis]
579 Wu JL, Su TH, Chen PJ, Chen YR. Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. Sci Rep 2022;12:5799. [PMID: 35388082 DOI: 10.1038/s41598-022-09713-9] [Reference Citation Analysis]
580 Lin N, Li J, Ke Q, Xin F, Zeng Y, Wang L, Liu J. Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review. PLoS One 2020;15:e0229870. [PMID: 32160231 DOI: 10.1371/journal.pone.0229870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
581 Ali S, Ali M, Paudyal V, Rasheed F, Ullah S, Haque S, Ur-Rehman T. A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients. Patient Prefer Adherence 2019;13:2089-100. [PMID: 31997877 DOI: 10.2147/PPA.S224937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
582 Tsurugai Y, Takeda A, Sanuki N, Eriguchi T, Ueno M. Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. Cureus 2021;13:e18624. [PMID: 34765376 DOI: 10.7759/cureus.18624] [Reference Citation Analysis]
583 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
584 Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Clin Exp Gastroenterol 2020;13:385-96. [PMID: 33061517 DOI: 10.2147/CEG.S256691] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
585 Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00135-7. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Reference Citation Analysis]
586 Acharya SK, Bopanna S. Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different? J Clin Exp Hepatol 2020;10:518-24. [PMID: 33029058 DOI: 10.1016/j.jceh.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
587 Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00385-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
588 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
589 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
590 Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, Vestito A, Festi D, Colecchia A. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151-63. [PMID: 34027932 DOI: 10.23736/S2724-5985.20.02793-2] [Reference Citation Analysis]
591 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
592 Wei JW, Fu SR, Zhang J, Gu DS, Li XQ, Chen XD, Zhang ST, He XF, Yan JF, Lu LG, Tian J. CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00198-3. [PMID: 34674948 DOI: 10.1016/j.hbpd.2021.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
593 Hu J, Zhang ZQ, Zhu W, Wu ZR, You Y, Liu Y, Su DW, Wang YB, Gong JP. Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background. Carcinogenesis 2020;41:1576-82. [PMID: 32188964 DOI: 10.1093/carcin/bgaa024] [Reference Citation Analysis]
594 Mähringer-Kunz A, Meyer FI, Hahn F, Müller L, Düber C, Pinto Dos Santos D, Galle PR, Weinmann A, Kloeckner R, Schotten S. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterol J 2021;9:590-7. [PMID: 34077613 DOI: 10.1002/ueg2.12098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
595 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Rennert C, Tauber C, Fehrenbach P, Heim K, Bettinger D, Sogukpinar Ö, Schuch A, Zecher BF, Bengsch B, Lang SA, Bronsert P, Björkström NK, Fichtner-Feigl S, Schultheiss M, Thimme R, Hofmann M. Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. Cells 2021;10:1369. [PMID: 34199483 DOI: 10.3390/cells10061369] [Reference Citation Analysis]
597 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
598 Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clinical Imaging 2020;62:63-8. [DOI: 10.1016/j.clinimag.2020.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
599 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Reference Citation Analysis]
600 Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Future Oncol 2021;17:1237-51. [PMID: 33307782 DOI: 10.2217/fon-2020-0758] [Reference Citation Analysis]
601 Mojtahed A, Núñez L, Connell J, Fichera A, Nicholls R, Barone A, Marieiro M, Puddu A, Arya Z, Ferreira C, Ridgway G, Kelly M, Lamb HJ, Caseiro-Alves F, Brady JM, Banerjee R. Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. Abdom Radiol (NY) 2022;47:143-51. [PMID: 34605963 DOI: 10.1007/s00261-021-03262-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
602 Ryu T, Takami Y, Wada Y, Sasaki S, Imamura H, Ureshino H, Saitsu H. Combined hepatectomy and microwave ablation for multifocal hepatocellular carcinoma: Long-term outcomes and prognostic factors. Asian J Surg 2021;44:186-91. [PMID: 32473893 DOI: 10.1016/j.asjsur.2020.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
603 Mao X, Guo Y, Lu Z, Wen F, Liang H, Sun W. Enhanced CT Textures Derived From Computer Mathematic Distribution Analysis Enables Arterial Enhancement Fraction Being an Imaging Biomarker Option of Hepatocellular Carcinoma. Front Oncol 2020;10:1337. [PMID: 32850426 DOI: 10.3389/fonc.2020.01337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
604 Strobel D. Using contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma - what we have and have not achieved. Ultraschall Med 2021;42:120-4. [PMID: 33845488 DOI: 10.1055/a-1347-1388] [Reference Citation Analysis]
605 Mähringer‐kunz A, Wagner F, Hahn F, Weinmann A, Brodehl S, Schotten S, Hinrichs JB, Düber C, Galle PR, Pinto dos Santos D, Kloeckner R. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. Liver Int 2019;40:694-703. [DOI: 10.1111/liv.14380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
606 Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
607 Luo J, Zhou K, Zhang B, Luo N, Bian J. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosis-Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrast-Enhanced MRI. J Magn Reson Imaging 2020;51:812-23. [PMID: 31245888 DOI: 10.1002/jmri.26845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
608 Zhang YL, Nie CH, Chen F, Zhou TY, Zhou GH, Zhu TY, Chen SQ, Chen XH, Wang HL, Wang BQ, Yu ZN, Jing L, He ZM, Sun JH. Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2020;10:1754. [PMID: 32984060 DOI: 10.3389/fonc.2020.01754] [Reference Citation Analysis]
609 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
610 Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia. Haemophilia 2021;27:100-7. [PMID: 33245832 DOI: 10.1111/hae.14220] [Reference Citation Analysis]
612 Gow P, Spelman T, Gardner S, Hellard M, Howell J. Estimates of the global reduction in liver disease-related mortality with increased coffee consumption: an analysis of the Global Burden of Disease Dataset. Aliment Pharmacol Ther 2020;52:1195-203. [PMID: 32794601 DOI: 10.1111/apt.16020] [Reference Citation Analysis]
613 Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered 2022;13:3108-21. [PMID: 35037556 DOI: 10.1080/21655979.2022.2025701] [Reference Citation Analysis]
614 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
615 Li HZ, Tan J, Tang T, An TZ, Li JX, Xiao YD. Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. J Hepatocell Carcinoma 2021;8:1311-22. [PMID: 34754838 DOI: 10.2147/JHC.S338456] [Reference Citation Analysis]
616 Cannella R, Vernuccio F, Antonucci M, Gagliano DS, Matteini F, Midiri M, Brancatelli G. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations? Eur Radiol 2021. [PMID: 34545444 DOI: 10.1007/s00330-021-08267-0] [Reference Citation Analysis]
617 Lee V, Seong J, Yoon S, Wong T, Wang B, Zhang J, Chiang C, Ho P, Dawson L. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology 2019;31:560-9. [DOI: 10.1016/j.clon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
618 Zhang Y, Liu X, Liu L, Chen J, Hu Q, Shen S, Zhou Y, Chen S, Xue C, Cui G, Yu Z. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:2514090. [PMID: 32399086 DOI: 10.1155/2020/2514090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
619 Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
620 Yang C, Chen J, Li Y, Huang X, Liu Z, Wang J, Jiang H, Qin W, Lv Y, Wang H, Wang C. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform 2021;22:bbaa295. [PMID: 33167027 DOI: 10.1093/bib/bbaa295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
621 Moctezuma-Velázquez C, Lewis S, Lee K, Amodeo S, Llovet JM, Schwartz M, Abraldes JG, Villanueva A. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Rep 2021;3:100364. [PMID: 34712933 DOI: 10.1016/j.jhepr.2021.100364] [Reference Citation Analysis]
622 Luerken L, Haimerl M, Doppler M, Uller W, Beyer LP, Stroszczynski C, Einspieler I. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Rofo 2022. [PMID: 35545102 DOI: 10.1055/a-1768-0954] [Reference Citation Analysis]
623 Nekvindova J, Mrkvicova A, Zubanova V, Hyrslova Vaculova A, Anzenbacher P, Soucek P, Radova L, Slaby O, Kiss I, Vondracek J, Spicakova A, Bohovicova L, Fabian P, Kala Z, Palicka V. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochem Pharmacol 2020;177:113912. [PMID: 32173367 DOI: 10.1016/j.bcp.2020.113912] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
624 Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Cheng YF, Wang JH, Yen YH, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg 2021:S0002-9610(21)00226-9. [PMID: 33840448 DOI: 10.1016/j.amjsurg.2021.03.065] [Reference Citation Analysis]
625 Kim SS, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, Nam SW, Cheong JY, Eun JW. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14:2646-2659. [PMID: 32525601 DOI: 10.1002/1878-0261.12745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
626 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
628 Kim JS, Lee JK, Baek SY, Yun HI. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdom Radiol (NY) 2020;45:211-9. [PMID: 31650374 DOI: 10.1007/s00261-019-02277-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
629 Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, Meng Y, Zhai J, Shan YF, Cheng SQ. Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Front Oncol 2022;12:839605. [PMID: 35387113 DOI: 10.3389/fonc.2022.839605] [Reference Citation Analysis]
630 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
631 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
632 Rodriguez De Santiago E, Téllez L, Guerrero A, Albillos A. Hepatocellular carcinoma after Fontan surgery: A systematic review. Hepatol Res 2021;51:116-34. [DOI: 10.1111/hepr.13582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
633 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology 2019;292:638-46. [PMID: 31287387 DOI: 10.1148/radiol.2019190183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
634 Zeng J, Zeng J, Huang Y, Liu J, Zeng J. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.07.007] [Reference Citation Analysis]
635 Lin SH, Wu KT, Wang CC, Huang KT, Chen KD, Lin CC, Hsu LW, Chiu KW. HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation. J Int Med Res 2021;49:3000605211034945. [PMID: 34344219 DOI: 10.1177/03000605211034945] [Reference Citation Analysis]
636 Li J, Yang L, Ma L, Lu Q, Luo Y. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis. Ultraschall Med 2021;42:187-93. [PMID: 33307595 DOI: 10.1055/a-1309-1568] [Reference Citation Analysis]
637 Jayaswal ANA, Levick C, Collier J, Tunnicliffe EM, Kelly MD, Neubauer S, Barnes E, Pavlides M. Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. Abdom Radiol (NY) 2021;46:1947-57. [PMID: 33247768 DOI: 10.1007/s00261-020-02860-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
638 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
639 Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol 2019; 25(40): 6094-6106 [PMID: 31686765 DOI: 10.3748/wjg.v25.i40.6094] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
640 Chen Y, Zeng J, Guo P, Zeng J, Liu J. Prognostic Significance of Platelet-to-Lymphocyte Ratio (PLR) in Extrahepatic Metastasis of Hepatocellular Carcinoma After Curative Resection. Cancer Manag Res 2021;13:1395-405. [PMID: 33603483 DOI: 10.2147/CMAR.S290738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Wen R, Lin P, Gao R, Wu Y, Peng J, Peng Y, Wen D, Yin H, Ma Z, Tang Z, He Y, Yang H. Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists. Abdom Radiol (NY) 2022;47:1798-805. [PMID: 35260943 DOI: 10.1007/s00261-022-03468-7] [Reference Citation Analysis]
642 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
643 Ren Y, Guo Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. Cancer Control 2022;29:10732748221076806. [PMID: 35343254 DOI: 10.1177/10732748221076806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
644 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
645 Matsuki Y, Matono T, Koda M, Miyoshi K, Sugihara T, Okano JI, Isomoto H. Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol 2020;133:109358. [PMID: 33126170 DOI: 10.1016/j.ejrad.2020.109358] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
646 Galun D, Bogdanovic A, Zivanovic M, Zuvela M. Short- and Long-Term Outcomes After Hepatectomy in Elderly Patients with Hepatocellular Carcinoma: An Analysis of 229 Cases from a Developing Country. J Hepatocell Carcinoma 2021;8:155-65. [PMID: 33791251 DOI: 10.2147/JHC.S297296] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
647 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
648 Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Hum Pathol 2021;113:39-46. [PMID: 33905775 DOI: 10.1016/j.humpath.2021.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
649 Mohammadi A, Bartholmae W, Woisetschläger M. Comparison of multiphase data from CT perfusion vs clinical 4-phase CT scans with respect to image quality, lesion detection, and LI-RADS classification in HCC patients. Heliyon 2022;8:e08757. [DOI: 10.1016/j.heliyon.2022.e08757] [Reference Citation Analysis]
650 Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? World J Gastroenterol 2021; 27(36): 6039-6052 [PMID: 34629818 DOI: 10.3748/wjg.v27.i36.6039] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
651 Troisi RI, Pegoraro F, Giglio MC, Rompianesi G, Berardi G, Tomassini F, De Simone G, Aprea G, Montalti R, De Palma GD. Robotic approach to the liver: Open surgery in a closed abdomen or laparoscopic surgery with technical constraints? Surg Oncol 2020;33:239-48. [PMID: 31759794 DOI: 10.1016/j.suronc.2019.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
652 Kuo YH, Yen YH, Chen YY, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol 2021;11:683341. [PMID: 34136408 DOI: 10.3389/fonc.2021.683341] [Reference Citation Analysis]
653 Li Q, Li JF, Mao XR. Application of artificial intelligence in liver diseases: From diagnosis to treatment. Artif Intell Gastroenterol 2021; 2(5): 133-140 [DOI: 10.35712/aig.v2.i5.133] [Reference Citation Analysis]
654 Liu D, Liu M, Su L, Wang Y, Zhang X, Long H, Kuang M, Xie X, Lin M. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome. J Vasc Interv Radiol 2019;30:1879-86. [PMID: 31669087 DOI: 10.1016/j.jvir.2019.07.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
655 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
656 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
657 Costa-Santos MP, Gonçalves A, Ferreira AO, Nunes J. Spontaneous regression of hepatocellular carcinoma: myth or reality? BMJ Case Rep 2020;13:e233509. [PMID: 32047089 DOI: 10.1136/bcr-2019-233509] [Reference Citation Analysis]
658 Lu Y, Zhang J, Wu Y. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. Mol Med Rep 2021;24:609. [PMID: 34184075 DOI: 10.3892/mmr.2021.12247] [Reference Citation Analysis]
659 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Reference Citation Analysis]
660 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
661 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
662 Jiang H, Liu X, Chen J, Wei Y, Lee JM, Cao L, Wu Y, Duan T, Li X, Ma L, Song B. Man or machine?Cancer Imaging. 2019;19:84. [PMID: 31806050 DOI: 10.1186/s40644-019-0266-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
663 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
664 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
665 Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du X, Liu L. Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med 2020;8:539. [PMID: 32411762 DOI: 10.21037/atm.2020.02.85] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
666 Cillo U, Bertacco A, Fasolo E, Carandina R, Vitale A, Zanus G, Gringeri E, D'Amico F, Bassi D, Neri D, Dadduzio V, Farinati F, Aliberti C. Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. J Surg Oncol 2019;120:956-65. [PMID: 31373009 DOI: 10.1002/jso.25651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
667 Mourad M, Mabrut J, Chellakhi M, Lesurtel M, Prevost C, Ducerf C, Rode A, Merle P, Mornex F, Mohkam K. Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. Future Oncology 2019;15:2517-30. [DOI: 10.2217/fon-2019-0127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
668 Colasanti M, Berardi G, Mariano G, Ferretti S, Meniconi RL, Guglielmo N, Ettorre GM. Laparoscopic Left Hepatectomy for Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11275-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
669 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:115-27. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 37.0] [Reference Citation Analysis]
670 Zhang H, Dong P, Guo S, Tao C, Chen W, Zhao W, Wang J, Cheung R, Villanueva A, Fan J, Ding H, Schrodi SJ, Zhang D, Zeng C. Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Med 2020;18:200. [PMID: 32741373 DOI: 10.1186/s12916-020-01667-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
671 Liu Y, Hu C, Qu X, Chen H, Liu L, Zhou L, Liu S, Li G, Zhou Y. Novel Role of Long Non-Coding RNA ASAP1-IT1 in Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:746896. [DOI: 10.3389/fonc.2022.746896] [Reference Citation Analysis]
672 Müller L, Gairing SJ, Kloeckner R, Foerster F, Weinmann A, Mittler J, Stoehr F, Emrich T, Düber C, Galle PR, Hahn F. Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. Cancers 2022;14:3574. [DOI: 10.3390/cancers14153574] [Reference Citation Analysis]
673 Huang CF, Yu ML. Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter? Clin Mol Hepatol 2019;25:168-71. [PMID: 30739433 DOI: 10.3350/cmh.2018.1014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
674 Edeline J, Garin E. Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90…. Journal of Hepatology 2020;72:1046-8. [DOI: 10.1016/j.jhep.2020.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
675 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
676 Fernández-Placencia R, Golse N, Cano L, Allard MA, Pittau G, Ciacio O, Cunha AS, Castaing D, Salloum C, Azoulay D, Cherqui D, Samuel D, Adam R, Vibert E. Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery 2020;168:17-24. [PMID: 32204923 DOI: 10.1016/j.surg.2020.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
677 Ren L, Chen D, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer 2021;21:817. [PMID: 34266388 DOI: 10.1186/s12885-021-08565-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
678 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
679 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Reference Citation Analysis]
680 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
681 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
682 Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
683 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
684 Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol 2019;42:1563-70. [PMID: 31455987 DOI: 10.1007/s00270-019-02317-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
685 Van Thai N, Thinh NT, Ky TD, Bang MH, Giang DT, Ha LN, Son MH, Tien DD, Lee HW. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol 2021;21:216. [PMID: 33980171 DOI: 10.1186/s12876-021-01805-6] [Reference Citation Analysis]
686 Cathomas M, Mertineit N, Kim-Fuchs C, Lachenmayer A, Maurer MH. Value of MRI/CT Image Fusion for Targeting "invisible" Lesions in Stereotactic Microwave Ablation (SMWA) of Malignant Liver Lesions: A Retrospective Analysis. Cardiovasc Intervent Radiol 2020;43:1505-14. [PMID: 32642989 DOI: 10.1007/s00270-020-02565-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
687 Wen K, Yan Y, Shi J, Hu L, Wang W, Liao H, Li H, Zhu Y, Mao K, Xiao Z. Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:809672. [PMID: 34977159 DOI: 10.3389/fmolb.2021.809672] [Reference Citation Analysis]
688 Long Y, Liang Y, Li S, Guo J, Wang Y, Luo Y, Wu Y. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies. Radiat Oncol 2021;16:68. [PMID: 33832536 DOI: 10.1186/s13014-021-01761-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
689 Schwarz S, Clevert DA, Ingrisch M, Geyer T, Schwarze V, Rübenthaler J, Armbruster M. Quantitative Analysis of the Time-Intensity Curve of Contrast-Enhanced Ultrasound of the Liver: Differentiation of Benign and Malignant Liver Lesions. Diagnostics (Basel) 2021;11:1244. [PMID: 34359327 DOI: 10.3390/diagnostics11071244] [Reference Citation Analysis]
690 Lee YS, Hyun MH, Yim SY, Kim JH, Yeon JE, Byun KS. Reply. Hepatology 2019;69:924. [PMID: 30325527 DOI: 10.1002/hep.30316] [Reference Citation Analysis]
691 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
692 Ratti F, Cipriani F, Fiorentini G, Catena M, Paganelli M, Aldrighetti L. Reappraisal of the advantages of laparoscopic liver resection for intermediate hepatocellular carcinoma within a stage migration perspective: Propensity score analysis of the differential benefit. J Hepatobiliary Pancreat Sci 2020;27:510-21. [PMID: 32189450 DOI: 10.1002/jhbp.736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
693 Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging 2022;22:1. [PMID: 34983668 DOI: 10.1186/s40644-021-00439-x] [Reference Citation Analysis]
694 Guo H, Huang J, Tan Y, Wu W, Huang T, Zhang N, Chen S, Zhang C, Xie X, Shuai X, Xu M. Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today 2022;43:101425. [DOI: 10.1016/j.nantod.2022.101425] [Reference Citation Analysis]
695 Georgiades C. If at First You Don't Succeed, TACE and TACE Again. Radiology 2021;298:693-4. [PMID: 33475470 DOI: 10.1148/radiol.2021204248] [Reference Citation Analysis]
696 Kim DH, Hong SB, Choi SH, Kim SY, Shim JH, Lee JS, Choi JI, Kim S. Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis. Gut 2022;71:212-3. [PMID: 33649047 DOI: 10.1136/gutjnl-2020-323615] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
697 Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L, Ding N, Zhang X, Zhai J, Qu Z. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front Oncol 2022;12:950266. [DOI: 10.3389/fonc.2022.950266] [Reference Citation Analysis]
698 Lee BC, Jeong YY, Heo SH, Kim HO, Park C, Shin SS, Cho SB, Koh YS. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol 2022:S1076-6332(21)00483-9. [PMID: 35151549 DOI: 10.1016/j.acra.2021.10.012] [Reference Citation Analysis]
699 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
700 Degasperi E, Galmozzi E, Pelusi S, D'Ambrosio R, Soffredini R, Borghi M, Perbellini R, Facchetti F, Iavarone M, Sangiovanni A, Valenti L, Lampertico P. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology 2020;72:1912-23. [PMID: 32762045 DOI: 10.1002/hep.31500] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
701 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
702 Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA. Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Kaunas) 2021;57:1000. [PMID: 34684036 DOI: 10.3390/medicina57101000] [Reference Citation Analysis]
703 Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
704 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
705 Fasolato S, Pigozzo S, Pontisso P, Angeli P, Ruscica M, Savarino E, De Martin S, Lupo MG, Ferri N. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med 2020;9:E3134. [PMID: 32998342 DOI: 10.3390/jcm9103134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
706 Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know. Semin Intervent Radiol 2021;38:405-11. [PMID: 34629706 DOI: 10.1055/s-0041-1732323] [Reference Citation Analysis]
707 Ippolito D, Famularo S, Giani A, Orsini EB, Pecorelli A, Pinotti E, Gandola D, Romano F, Sironi S, Bernasconi DP, Gianotti L. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI. Digestive and Liver Disease 2019;51:1438-45. [DOI: 10.1016/j.dld.2019.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
708 Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, Tormene D, Burra P, Senzolo M, Simioni P. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.009] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
709 Huo TI, Liao JI, Ho SY. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor? Liver Int 2022. [PMID: 35460171 DOI: 10.1111/liv.15279] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
710 Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O; Liver Cancer Study Group of Japan. Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. Br J Surg 2021;108:412-8. [PMID: 33793713 DOI: 10.1093/bjs/znaa109] [Reference Citation Analysis]
711 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
712 Bhakta S, Mishra P. Molecularly imprinted polymer-based sensors for cancer biomarker detection. Sensors and Actuators Reports 2021;3:100061. [DOI: 10.1016/j.snr.2021.100061] [Reference Citation Analysis]
713 Parisse S, Ferri F, Persichetti M, Mischitelli M, Abbatecola A, Di Martino M, Lai Q, Carnevale S, Lucatelli P, Bezzi M, Rossi M, De Santis A, Spagnoli A, Ginanni Corradini S. Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. Sci Rep 2021;11:15184. [PMID: 34312420 DOI: 10.1038/s41598-021-94509-6] [Reference Citation Analysis]
714 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
715 da Fonseca L, Carrilho FJ. Expanding TACTICS trial into a different setting in hepatocellular carcinoma. Ann Hepatol 2020;19:230-1. [PMID: 32139261 DOI: 10.1016/j.aohep.2020.02.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
716 Ridouani F, Ghosn M, Doustaly R, Gonzalez-Aguirre AJ, Ziv E, Solomon SB, Edward Boas F, Yarmohammadi H. Accuracy of a CBCT-based virtual injection software for vessel detection during hepatic arterial embolization. Eur J Radiol 2022;150:110273. [PMID: 35338952 DOI: 10.1016/j.ejrad.2022.110273] [Reference Citation Analysis]
717 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
718 Ardito F, Famularo S, Aldrighetti L, Grazi GL, DallaValle R, Maestri M, Jovine E, Ruzzenente A, Baiocchi GL, Ercolani G, Griseri G, Frena A, Zanus G, Zimmitti G, Antonucci A, Crespi M, Memeo R, Romano F, Giuliante F; HE.RC.O.LE.S. Group. The Impact of Hospital Volume on Failure to Rescue after Liver Resection for Hepatocellular Carcinoma: Analysis from the HE.RC.O.LE.S. Italian Registry. Ann Surg 2020;272:840-6. [PMID: 32889868 DOI: 10.1097/SLA.0000000000004327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
719 Bannaga AS, Kvasnik F, Persaud K, Arasaradnam RP. Differentiating cancer types using a urine test for volatile organic compounds. J Breath Res 2020;15:017102. [PMID: 33086204 DOI: 10.1088/1752-7163/abc36b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
720 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
721 Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
722 Schmelzle M, Krenzien F, Schöning W, Pratschke J. Laparoscopic liver resection: indications, limitations, and economic aspects. Langenbecks Arch Surg 2020;405:725-35. [PMID: 32607841 DOI: 10.1007/s00423-020-01918-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
723 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
724 Seo N, Kim MJ, Rhee H. Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol 2019;29:3761-71. [PMID: 30859282 DOI: 10.1007/s00330-019-06052-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
725 Zhou Q, Tuo F, Li R, Wang X, Wang J, Huang Z, Chen M, Huang J. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2020;10:578763. [PMID: 33251141 DOI: 10.3389/fonc.2020.578763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
726 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
727 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
728 Bucalau AM, Tancredi I, Pezzullo M, Covas A, Verset G. Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. Acta Gastroenterol Belg 2021;84:371-4. [PMID: 34217191 DOI: 10.51821/84.2.371] [Reference Citation Analysis]
729 Karaoğullarindan Ü, Gümürdülü Y, Üsküdar O, Odabaş E, Güler HS, Delik A, Kuran S. Prognostic factors of elderly patients with hepatocellular carcinoma: should we be more courageous in treatment? Eur J Gastroenterol Hepatol 2022;34:956-60. [PMID: 35830357 DOI: 10.1097/MEG.0000000000002396] [Reference Citation Analysis]
730 Wu L, Tsilimigras DI, Farooq A, Hyer JM, Merath K, Paredes AZ, Mehta R, Sahara K, Shen F, Pawlik TM. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis. Cancer 2019;125:3767-75. [PMID: 31299092 DOI: 10.1002/cncr.32396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
731 Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol 2022. [PMID: 35881180 DOI: 10.1007/s00330-022-09000-1] [Reference Citation Analysis]
732 Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
733 Ward EM, Sherif AE, O'Neill S, Hughes M, Ireland H, Wigmore SJ, Adair A. Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Ann Transplant 2021;26:e931980. [PMID: 34326301 DOI: 10.12659/AOT.931980] [Reference Citation Analysis]
734 Kim AK, Hamilton JP, Lin SY, Chang T, Hann H, Hu C, Lou Y, Lin Y, Gade TP, Park G, Luu H, Lee T, Wang J, Chen D, Goggins MG, Jain S, Song W, Su Y. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. [DOI: 10.1038/s41416-022-01706-9] [Reference Citation Analysis]
735 Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
736 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
737 Kim TS, Lee M, Park M, Kim SY, Shim MS, Lee CY, Choi DH, Cho Y. Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1. Int J Mol Sci 2021;22:10027. [PMID: 34576192 DOI: 10.3390/ijms221810027] [Reference Citation Analysis]
738 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
739 Dang H, Chen L, Tang P, Cai X, Zhang W, Zhang R, Huang A, Tang H. LINC01419 promotes cell proliferation and metastasis in hepatocellular carcinoma by enhancing NDRG1 promoter activity. Cell Oncol (Dordr) 2020;43:931-47. [PMID: 32557341 DOI: 10.1007/s13402-020-00540-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
740 Narita K, Nakamura Y, Higaki T, Nishihara T, Harada K, Takizawa M, Shirase R, Bito Y, Akagi M, Honda Y, Iida M, Awai K. Utility of Radial Scanning for the Identification of Arterial Hypervascularity of Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced Magnetic Resonance Images. J Comput Assist Tomogr 2021;45:359-66. [PMID: 33661153 DOI: 10.1097/RCT.0000000000001139] [Reference Citation Analysis]
741 Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, Weinmann A, Marquardt JU, Vermehren J, Waidmann O. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9. [DOI: 10.1007/s00432-018-2780-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
742 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
743 Espejo-Cruz ML, González-Rubio S, Zamora-Olaya J, Amado-Torres V, Alejandre R, Sánchez-Frías M, Ciria R, De la Mata M, Rodríguez-Perálvarez M, Ferrín G. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int J Mol Sci 2021;22:13073. [PMID: 34884878 DOI: 10.3390/ijms222313073] [Reference Citation Analysis]
744 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
745 Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
746 D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2021:S0168-8278(21)02043-2. [PMID: 34592366 DOI: 10.1016/j.jhep.2021.09.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
747 Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, Dell'Acqua V, Høyer M, Jereczek-Fossa BA. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol 2019;58:1706-13. [PMID: 31464155 DOI: 10.1080/0284186X.2019.1657942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
748 Roderburg C, Berres ML, Wree A, Loosen SH, Luedde T, Trautwein C. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visc Med 2019;35:43-6. [PMID: 31312649 DOI: 10.1159/000497465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
749 Soong RS, Chen YC, Chou TC, Chiang PH, Chen WM, Chiang MF, Shia BC, Wu SY. A Novel Predictive Scoring System for 90-Day Mortality among Patients with Hepatocellular Cell Carcinoma Receiving Major Hepatectomy. Cancers (Basel) 2022;14:1398. [PMID: 35326550 DOI: 10.3390/cancers14061398] [Reference Citation Analysis]
750 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
751 Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver Imaging Reporting and Data System: Review of Pros and Cons. Semin Liver Dis 2021. [PMID: 34298576 DOI: 10.1055/s-0041-1732356] [Reference Citation Analysis]
752 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
753 Zeisel MB, Guerrieri F, Levrero M. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:1715. [PMID: 33923385 DOI: 10.3390/jcm10081715] [Reference Citation Analysis]
754 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
755 Li Y, Zhang M, Li X, Wang Y, Wang Y, Li Y, Zhu H, Ding H, Li X, Sun S. Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p. J Immunol Res 2022;2022:5003930. [PMID: 35528616 DOI: 10.1155/2022/5003930] [Reference Citation Analysis]
756 Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol 2021;4:747. [PMID: 34135460 DOI: 10.1038/s42003-021-02257-0] [Reference Citation Analysis]
757 Peng Z, Wu X, Li J, Pang H, Zhang Y, Lin M, Wang Z, Xiao H, Li B, Chen M, Feng S, Kuang M, Chen S. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Int J Hyperthermia 2022;39:688-96. [PMID: 35469522 DOI: 10.1080/02656736.2022.2051613] [Reference Citation Analysis]
758 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Reference Citation Analysis]
759 Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol 2019;54:905-12. [PMID: 31287338 DOI: 10.1080/00365521.2019.1632925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
760 Tipaldi MA, Ronconi E, Lucertini E, Krokidis M, Zerunian M, Polidori T, Begini P, Marignani M, Mazzuca F, Caruso D, Rossi M, Laghi A. He